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ABSTRACT 
Fibrosis is caused by scar tissue formation in internal organs and is associated 
with 45% of deaths in the U.S. Pentraxins are a group of evolutionarily conserved 
proteins that have profound effects of the innate immune system and regulate the 
development of fibrosis. The pentraxin Serum Amyloid P (SAP) alleviates fibrosis in 
mice and two human clinical trials, whereas C-reactive protein (CRP) which resembles 
SAP exacerbates fibrosis. Surprisingly, these two pentraxins bind the same Fc receptors 
(FcR) with similar affinities but have opposite effects. In this dissertation, I elucidate 
the role of FcR in the regulation of the innate immune system by pentraxins. I find that 
although FcR play a role in the regulation of immune cells by SAP, they are not 
necessary for SAP effects. SAP mainly uses the C-type lectin receptor DC-SIGN to alter 
immune responses and through its interaction with DC-SIGN SAP differentiates itself 
from CRP. I also found that a polycyclic aminothiazole DC-SIGN ligand and anti-DC-
SIGN antibodies mimic the effects of SAP in vitro. In mice, the aminothiazole alleviates 
acute lung inflammation and pulmonary fibrosis. The aminothiazole alleviates 
pulmonary fibrosis by upregulating the anti-inflammatory cytokine IL-10 in lung 
epithelial cells. Together, these results suggest that SAP activates DC-SIGN to regulate 
the innate immune system differently from CRP, and that the aminothiazole and anti-
DC-SIGN antibodies are potential therapeutics for fibrosis. 
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NOMENCLATURE 
CRP C-reactive protein 
CRP N32A Glycosylated C-reactive protein 
DC-SIGN Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin 
FcR Fc receptors 
FcR Fc common -chain 
HEK293 Human embryonic kidney cells 
IFN- Interferon  
IL-8 Interleukin 8 
IL-10 Interleukin 10 
iNOS Inducible nitric oxide synthase 
ITAM Immunoreceptor tyrosine-based activation motif 
NPTX1 Neuronal Pentraxin 1 
NPTX2 Neuronal Pentraxin 2 
NPTXR Neuronal Pentraxin receptor 
PBMC Peripheral blood mononuclear cells 
PTX3 Pentraxin 3 
SAP Serum Amyloid P 
SAP-f Alexa Fluor 647-labeled SAP 
SAP (NA) Desialylated SAP 
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TGF- Tumor growth factor  
TNF- Tumor Necrosis Factor  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW
*
 
 
The mammalian immune system is organized into two arms: innate and adaptive 
immunity. Innate immunity is evolutionary more ancient and constitutes the first line of 
defense against foreign pathogens (1). In vertebrates, adaptive immunity complements 
innate immunity and provides immunological memory (2). Pathogen recognition 
molecules such as pentraxins are at the core of innate immunity (3, 4). Pentraxins 
recognize evolutionarily conserved pathogen molecules such as C-polysaccharide, 
regulate complement activation, and bind apoptotic cells, to initiate and synchronize the 
immune response (4-7).  
Pentraxins are a family of conserved proteins that appeared early on during the 
evolution of innate immunity (8), and have a 200 amino acid long pentraxin domain with 
a conserved pentraxin signature (HxCxS/TWxS, where x stands for any amino acid) (9). 
Pentraxins are organized into two groups: the short and the long pentraxins. The short 
pentraxins are identified by their pentameric structure consisting of 25 kDa monomers 
and include C-reactive protein (CRP) and Serum Amyloid P (SAP) (for a review on CRP 
see (10)). The long pentraxins have a N-terminal domain attached to a pentraxin domain, 
and include PTX3, PTX4, guinea pig apexin, neuronal pentraxin 1 (NPTX1), NPTX2, 
and neuronal pentraxin receptor (NPTXR) (for reviews see (4, 9, 11, 12)).  
                                                 
*
 Reprinted with permission from The Journal of Leukocyte Biology. Cox, N., D. Pilling, and R. H. 
Gomer. Serum amyloid P: a systemic regulator of the innate immune response. J Leukoc Biol. 2014. Epub 
2014/05/09. doi: 10.1189/jlb.1MR0114-068R. Copyright © 2009 The Journal of Leukocyte Biology. 
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The short pentraxins CRP and SAP are pattern recognition molecules secreted by 
the liver that interact with pathogens and cell debris to promote their removal by 
macrophages and neutrophils (13). SAP binds to rough lipopolysaccharide, and lack of 
SAP causes hypersensitivity to laboratory strains of E. coli (14). In addition, CRP and 
SAP interact with components of the complement pathway to regulate complement 
activation (15, 16). However, the regulation of the innate immune system by SAP is not 
limited to its effects on the complement pathway and phagocytosis. SAP directly binds 
to monocytes, neutrophils, and macrophages to modify their activation and alter their 
differentiation to modulate the immune response. 
 
Regulation of neutrophil function by SAP 
At the onset of inflammation, neutrophils are recruited to the damaged tissue 
where they release reactive oxygen species and promote clearance of pathogens and cell 
debris. This recruitment is mediated by cytokines, tissue damage, complement 
activation, and changes in adhesion receptors on the surface of endothelial cells (17-19). 
The migration and activation of neutrophils is tightly regulated by factors expressed and 
secreted by endothelial cells and macrophages (17). However, factors present in plasma 
also affect neutrophils (17). 
 
SAP binds to neutrophils to regulate their function 
One circulating factor that regulates neutrophil accumulation in tissues is SAP 
(20). SAP binds to human and murine neutrophils and decreases TNF- and IL-8-
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induced neutrophil binding to extracellular matrix components (20, 21). SAP also 
reduces TNF-induced human neutrophil adhesion to endothelial cells (22). One 
possible mechanism underlying the effect of SAP on neutrophils involves SAP binding 
to, and thus potentially blocking, the adhesion receptor L-selectin on neutrophils (22). 
This is supported by the observation that adding anti-L-selectin antibodies to human 
neutrophils decreases their binding to umbilical vein endothelial cells (22) A second 
possible mechanism involves SAP binding to Fc receptors (FcR) on neutrophils (23-
25). Fc receptors are best known for binding IgG, and in humans include the activating 
receptors FcRI, FcRIIa, FcRIIIa, FcRIIIb, and the inhibitory receptor FcRIIb (26, 
27). FcRIIa and FcRIIIb are expressed at high levels on human neutrophils, and 
activation of FcRIIa by SAP results in the phosphorylation of the immunoreceptor 
tyrosine-based activation motif (ITAM) in the cytosolic region of FcRIIa (28). ITAM 
activation can then lead to conformational changes in adhesion receptors on neutrophils 
via inside-out signaling (29). Much remains to be investigated about the effects of SAP 
on neutrophils, and most likely this effect involves a variety of receptors including Fc 
receptors and L-selectin. 
 
SAP inhibits neutrophil spreading  
In addition to decreasing neutrophil adhesion, SAP also decreases human 
neutrophil spreading, a necessary step for cell polarization and migration (20, 30-33). 
Paradoxically, SAP does not influence human neutrophil migration in response to fMLP 
in a Boyden chamber (20). This inconsistency may be due to the differences in the 
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adhesion receptors used during neutrophil migration on matrix proteins and after 
stimulation with chemotactic stimuli in a Boyden chamber. On fibronectin, neutrophils 
use the 1 (VLA-4 and VLA-5) integrins to migrate, whereas in an uncoated Boyden 
chamber, 2 (CD11b/CD18) integrins are the key adhesion receptors (34, 35). SAP may 
act as a chemoattractant of human neutrophils, although this finding has not been 
replicated (21). Alternatively, it is possible that the timing of stimuli (i.e. SAP) could 
determine how neutrophil spreading and migration is influenced.  
 
Indirect effects of SAP on neutrophils 
Neutrophils secrete proteases such as elastase to degrade the extracellular matrix 
and facilitate tissue infiltration (for a review see (36)). SAP but not CRP binds to 
neutrophil elastase and inhibits its enzymatic activity (37). This can hinder neutrophil 
extravasation and the secondary damage caused by the proteolytic activity of elastase in 
tissues (36-40). SAP also induces macrophages to produce the anti-inflammatory 
cytokine interleukin (IL)-10, which in turn decreases TNF- and CXCL8 (IL-8) 
production. This then results in decreased neutrophil recruitment (23, 41-43). These 
observations suggest that SAP regulates many aspects of neutrophil biology to exert an 
anti-inflammatory effect, and set a threshold for neutrophil recruitment and activation 
(Fig. 1). In agreement with this, we have observed that SAP injections can decrease 
neutrophil accumulation in a mouse model of acute respiratory distress syndrome (20).  
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SAP inhibits monocyte to fibrocyte differentiation 
Monocytes present within the blood are attracted to sites of injury where they 
differentiate into macrophages, dendritic cells, or fibrocytes (44, 45). Fibrocytes are 
spindle-shaped fibroblast-like cells, and at least in part, mediate tissue repair and fibrosis 
(for a review see (45)). Fibrocytes have been detected in human pathological conditions 
including pulmonary fibrosis, keloid scars, asthma, chronic kidney disease, and 
nephrogenic systemic fibrosis (45-49). In addition to contributing to the mass of fibrotic 
lesions, fibrocytes promote angiogenesis, which can then promote the growth of the 
lesion, and secrete TGF-, which activates resident fibroblasts (50). Fibrocyte 
differentiation is regulated by several factors including cytokines, toll like receptor 
ligands, semaphorins, and hyaluronic acid (45, 51-53). We found that when human, 
mouse, or rat peripheral blood mononuclear cells (PBMCs) were cultured in serum-free 
media, some of the cells became fibrocytes after 3-5 days (54). The fibrocytes did not 
appear during this timeframe when serum was present (54). We purified the fibrocyte 
differentiation inhibitor from human serum and identified it as SAP (54). When PBMCs 
were cultured in serum that was depleted of SAP, fibrocytes rapidly appeared, indicating 
that SAP is the main endogenous inhibitor of fibrocyte differentiation in the blood. In 
agreement with this, we observed that depleting SAP from dermal wounds in pigs can 
facilitate fibrocyte differentiation and scar tissue formation (55). We also tested whether 
SAP could inhibit fibrocyte differentiation and fibrosis in bleomycin-induced lung 
fibrosis (56). We found that SAP injections led to reduced numbers of fibrocytes in the 
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Figure 1: SAP inhibits neutrophil recruitment. 
A) In response to chemoattractants such as CXCL8, neutrophils begin to migrate into the 
tissue in a process that involves neutrophil rolling, arrest, and extravasation. All these 
steps are mediated by adhesion receptors on the endothelial cells and on neutrophils. B) 
In the presence of high levels of SAP, neutrophil recruitment to the tissue is reduced as 
SAP-induced IL-10 inhibits the secretion of CXCL8. SAP also reduces neutrophil 
adhesion by preventing L-selectin binding to adhesion receptors on endothelial cells. 
SAP may further affect neutrophil adhesion by regulating adhesion receptors on 
neutrophils by inside-out signaling via Fc receptors. In addition, SAP reduces 
neutrophil migration by inhibiting neutrophil spreading and elastase activity. 
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lungs and reduced fibrosis in rats and mice, and that delaying SAP injections until 
inflammation and fibrosis was already apparent could also reduce symptoms (56). 
 
SAP binds to Fcreceptors to inhibit fibrocyte differentiation 
SAP inhibits fibrocyte differentiation in part by binding to Fcreceptors (57). In 
support of this, we have found that cross-linked but not monomeric IgG inhibits 
fibrocyte differentiation, and that blocking the signal transduction pathway of the Fc 
receptors with pharmacological inhibitors blocks the ability of both SAP and cross-
linked IgG to inhibit fibrocyte differentiation (58). In mice, deletion of the Fc common 
-chain (FcR), which is necessary for FcRI and FcRIIIa signaling, significantly 
reduces sensitivity to SAP (23, 57, 59). However, deletions of FcRIIb, FcRIII, and 
FcRIV do not affect sensitivity to SAP (57). We found similar results using siRNA 
knockdowns of human receptors (57). However, in all these conditions, SAP still caused 
some inhibition of fibrocyte differentiation (23, 57), indicating the presence of unknown 
SAP receptors on monocytes. These observations suggest that SAP in part uses FcRI 
and FcR to inhibit fibrocyte differentiation (Fig. 2).  
 
SAP regulates murine macrophage polarization 
Macrophages are considered one of the most important innate effector cells (for reviews 
see (60-62)). Macrophages can be classified into the classically activated 
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Figure 2: SAP inhibits fibrocyte formation.  
A) When SAP is present in the tissue, as is the case in early inflammation, SAP binds to 
FcRI to inhibit fibrocyte differentiation. Deletion of the FcRI or the Fc common -
chain significantly reduces the inhibitory effect of SAP. B) At late stages of 
inflammation when SAP levels are low, monocytes differentiate into fibroblast-like cells 
called fibrocytes. Fibrocytes then secrete extracellular matrix components such as 
collagen and extracellular modifying enzymes to restore the architecture of the damaged 
tissue. 
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macrophages (M1) and the alternatively activated macrophages (M2) (60, 63). M1 
macrophages are induced in response to TNF-, IFN- and specific Toll-like receptor. 
M2 is a general term for several overlapping macrophage subsets which are induced in 
response to IL-4, IL-10, IL-13, and SAP (23, 60, 64).The role of M2 macrophages in the 
agonists (60, 64). The classically activated M1 macrophages modulate host defense 
against intracellular pathogens, tumor cells, and tissue debris, but are also responsible for 
tissue damage associated with their release of reactive oxygen species (60, 63, 65-67). 
immune system is highly dependent on the activating stimuli (i.e. IL-10 vs IL-4) and the 
environmental context. The alternatively activated M2 macrophages can be classified 
into three main groups: immuno-regulatory macrophages, pro-fibrotic/wound-healing 
macrophages, and tumor associated macrophages (60, 63, 68, 69). The hallmark of 
immuno-regulatory macrophages in both humans and mice is high levels of the anti-
inflammatory cytokine IL-10 and low levels of the pro-inflammatory cytokine IL-12 
(60). Wound-healing macrophages express high levels of IL-10 and IL-12, whereas 
tumor associated macrophages are identified by their secretion of angiogenic factors (60, 
68). 
 
SAP affects macrophages in mouse models 
In a mouse model of systemic lupus erythematosus, macrophages in the kidneys 
have elevated expression of IL-10, iNOS, and TNF-(64)IL-10 is a marker for M2 
macrophages, whereas iNOS and TNF- are typically associated with M1 macrophages 
(60, 64). When the mice were injected with SAP, the expression of the M2 markers IL-
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10 and arginase 1 in the kidney macrophages was increased, while the levels of the M1 
markers iNOS and TNF-decreased (64). This change in gene expression involved the 
phosphatidylinositol 3-Kinase/Akt–ERK signaling pathway, and indicates a shift 
towards an immuno-regulatory phenotype in macrophages (64).  
In mouse models of renal fibrosis, SAP injections decreased expression of the 
M1 markers Mip2a and IL-1β, and the pro-fibrotic M2 markers CCL17 and CCL22 on 
renal macrophages (23, 60). These changes were accompanied by a significant increase 
in the levels of IL-10 (23). In IL-10 and FcR knockout mice, the effects of SAP on 
renal fibrosis was reduced (23). Together, these observations suggest that SAP in two 
different models of renal injuries polarizes macrophages toward an immuno-regulatory 
phenotype.  
In TGF--driven mouse models of pulmonary fibrosis, SAP alleviates fibrosis in 
part through its effect on macrophages (70, 71). In this model of pulmonary fibrosis, 
SAP injections decreased M2 markers while increasing the M1 marker CXCL10 on 
pulmonary macrophages (60, 70). This is in stark contrast to the role of SAP in renal 
injuries, where it promotes immuno-regulatory macrophages and decreases M1 
macrophages. This inconsistency may be attributed to differences that exist in the milieu 
of kidneys and lungs. In support of this, similar to TGF- driven pulmonary fibrosis, 
SAP attenuated M2 macrophage activation in the spore-induced allergic airway disease 
of mice (60, 72). Furthermore, in spore-induced allergic airway disease, SAP injections 
increased expression of the M1 marker IFN- in lung macrophages while not 
significantly altering levels of the immuno-regulatory marker IL-10 (72). Together, these 
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observations suggest that SAP has a significant role in regulating macrophage 
polarization, but the outcome is tissue dependent (Fig. 3). 
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Figure 3: SAP inhibits pro-fibrotic macrophages in mice.  
SAP attenuates pro-fibrotic macrophages in renal and pulmonary injuries of mice in an 
FcR-mediated manner. SAP also opsonizes cell debris to promote their removal by 
macrophages. 
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CHAPTER II 
DISTINCT FCRECEPTORS MEDIATE THE EFFECT OF SERUM AMYLOID P 
ON NEUTROPHIL ADHESION AND FIBROCYTE DIFFERENTIATION
*
 
 
Summary 
The plasma protein Serum Amyloid P (SAP) reduces neutrophil adhesion, 
inhibits the differentiation of monocytes into fibroblast-like cells called fibrocytes, and 
promotes phagocytosis of cell debris by macrophages. Together, these effects of SAP 
reduce key aspects of inflammation and fibrosis, and SAP injections improve lung 
function in pulmonary fibrosis patients. SAP functions are mediated in part by Fc 
receptors, but the contribution of each Fc receptor is not fully understood. We found 
that amino acids Q55 and E126 in human SAP affect human fibrocyte differentiation and 
SAP binding to FcRI. E126, K130, and Q128 affect neutrophil adhesion and SAP 
affinity for FcRIIa. Q128 also affects phagocytosis by macrophages and SAP affinity 
for FcRI. All the identified functionally significant amino acids in SAP form a binding 
site that is distinct from the previously described SAP-FcRIIa binding site. Blocking 
FcRI with an IgG blocking antibody reduces the SAP effect on fibrocyte differentiation, 
and ligating FcRIIa with antibodies reduces neutrophil adhesion. Together, these results 
                                                 
*
 Reprinted with permission from The Journal of Immunology. Cox, N., D. Pilling, and R. H. Gomer. 
Distinct fcgamma receptors mediate the effect of serum amyloid p on neutrophil adhesion and fibrocyte 
differentiation. J Immunol. 2014;193(4):1701-8. Copyright © 2013 The American Association of 
Immunologists, Inc. http://www.jimmunol.org/ 
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suggest that SAP binds to FcRI on monocytes to inhibit fibrocyte differentiation, and 
binds to FcRIIa on neutrophils to reduce neutrophil adhesion. 
 
Introduction 
Aberrant scar tissue formation is the hallmark of fibrosing diseases such as end-
stage kidney disease, liver cirrhosis, pulmonary fibrosis, and congestive heart disease 
(45, 73, 74). The inappropriate scar tissue in fibrosis ultimately leads to organ failure 
and/or death. Fibrosing diseases are associated with 45% of deaths in the US (73, 75).  
Serum Amyloid P component (SAP) is a pentameric protein that belongs to the 
pentraxin family of evolutionarily conserved proteins. Pentraxins also include C-reactive 
protein (CRP) and the long pentraxin PTX3 (11). SAP, CRP, and PTX3 all have 
regulatory roles in the immune system (4, 9, 76). Injections of SAP inhibit inflammation 
and fibrosis in mouse models of pulmonary fibrosis, ischemic cardiac fibrosis, and renal 
fibrosis (20, 23, 56, 77), and in a phase 1b clinical trial, SAP injections appear to 
improve lung function in pulmonary fibrosis patients (78). 
At the onset of tissue damage and inflammation, neutrophils are recruited to the 
tissue in response to chemokines such as CXCL2 and CXCL8 (IL-8) to remove 
pathogens and/or cell debris via phagocytosis (17). This migration and activation of 
neutrophils is tightly regulated by factors expressed and secreted by endothelial cells, 
macrophages and other cell types (17). When this regulation is compromised, the 
elevated influx of neutrophils and recruitment of other immune cells by activated 
neutrophils can cause severe organ damage and fibrosis (17, 40, 79). SAP binds 
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neutrophils to inhibit their spreading and adhesion to components of extracellular matrix 
and endothelial cells (20, 80). Injections of SAP decrease the infiltration of neutrophils 
into the lungs following bleomycin insult in mice (20). However, the mechanism for this 
function is not well understood. 
Following neutrophil migration into the inflammation site, CD14
+
 monocytes 
enter and differentiate into macrophages and fibrocytes (45). Fibrocytes are CD45
+
 
collagen I
+
 fibroblast-like cells that share characteristics of both hematopoietic and 
stromal cells (81). Fibrocytes are found in healing dermal wounds and some fibrotic 
lesions, and secrete collagen and enzymes which modify the extracellular matrix (45, 55, 
56, 77, 82). SAP inhibits fibrocyte differentiation partly through a group of receptors 
called Fcγ receptors (23, 25, 57, 59, 83). These receptors bind IgG and consist of FcγRI, 
FcγRIIa, FcγRIIb, FcγRIIIa, and FcγRIIIb (84). We have previously shown that FcγRI is 
one of the receptors responsible for the effect of SAP on fibrocyte differentiation in both 
humans and mice (57). SAP also binds the IgA receptor FcαRI (85).  
In addition to modifying neutrophil adhesion and monocyte differentiation, SAP 
can also enhance phagocytosis of cell debris by professional phagocytes such as 
macrophages (24, 25). The SAP pentamer forms a flat disk, and binds to bacteria and 
cell debris on one surface, and to Fcγ receptors on the other surface, to promote 
phagocytosis by cells (25). Previous studies have implicated FcγRI as the key receptor 
for SAP-induced phagocytosis, but the precise role of each Fcγ receptor in this process is 
unclear (24, 25).  
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In this report, we examined how SAP interacts with Fc receptors to regulate 
different aspects of the immune system. We found that SAP inhibits fibrocyte 
differentiation and promotes phagocytosis by macrophages through FcγRI, while it 
reduces neutrophil adhesion via FcγRIIa. Using site-directed mutagenesis we determined 
that although the same site on SAP affects monocytes, macrophages, and neutrophils, it 
is possible to affect specific SAP functions without altering the other functions in an 
appreciable way. In addition, we identified a novel Fcγ receptor binding site that is 
distinct from the site previously identified in a co-crystal structure of SAP and FcγRIIa 
(83). 
Materials and methods 
PBMC and neutrophil isolation, cell culture, fibrocyte and macrophage differentiation 
Human peripheral blood was collected into heparin tubes (BD Bioscience, San 
Jose, CA) from healthy adult volunteers who gave written consent and with specific 
approval from the Texas A&M University human subjects Institutional Review Board. 
Peripheral blood mononuclear cells (PBMC) were isolated from the blood using Ficoll-
Paque Plus (GE Healthcare Biosciences, Piscataway, NJ), as described previously (86). 
PBMCs were cultured in Fibrolife (LifeLine Cell Technology, Walkersville, MD) 
defined serum-free medium (SFM) in the presence or absence of SAP variants as 
previously described (57). To determine the contribution of each Fc receptor to the SAP 
effect on fibrocyte differentiation, we incubated PBMCs with 5 µg/ml of F(ab′)2 
fragments of either anti-FcRI antibody clone 10.1 (mouse IgG1, Ancell, Bayport, MN), 
anti-FcRII antibody clone 7.3 (mouse IgG1, Ancell), anti-FcRIII antibody clone 3G8 
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(mouse IgG1, Ancell), or a mouse IgG1 isotype control (Ancell) in the presence and 
absence of SAP.  Fibrocytes were identified and counted based on their elongated 
spindle-shaped morphology in five different 900 µm-diameter fields of view per well 
(86-88). PBMCs were incubated overnight in RPMI-1640 (Lonza, Allendale, NJ) with 
10% fetal bovine serum (Caisson Laboratories, North Logan, UT) to generate 
macrophages, as described previously (25). Neutrophils were isolated from blood using 
Lympholyte-poly (Cedarlane Laboratories, Hornby, BC, Canada) following the 
manufacturer’s protocol and resuspended in 2% BSA (fraction V, A3059; Sigma-
Aldrich) in RPMI-1640 (20, 89). HEK293 cells (Life Technologies, Grand Island, NY) 
were cultured in Freestyle (Life Technologies) medium following the manufacturer’s 
protocol. K562 cells (ATCC, Manassas, VA) were grown in RPMI-1640 with 10% fetal 
bovine serum (Caisson). 
 
SAP variant expression, purification, size exclusion chromatography, and labeling 
Starting with the previously described SAP expression vector (57), SAP variants 
were generated with a QuickChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA) following the manufacturer’s protocol, and the DNA 
sequences of the constructs were verified. SAP variants were expressed in HEK293 cells 
as described previously and then purified by affinity purification (57). Briefly, cell 
supernatants from the SAP-expressing HEK293 cells were clarified by centrifugation at 
300 x g. 1 M CaCl2 was added to the supernatant to a final concentration of 2 mM, and 
the cell supernatant was then mixed with 1 ml of a 50% slurry of Sepharose Fast Flow 
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(GE Healthcare BioSciences, Piscataway, NJ, USA) in 20 mM Tris, 140 mM NaCl, 2 
mM CaCl2, pH 7.4 for 1 h. The Sepharose beads were collected and washed 3 times with 
15 ml wash buffer (20 mM Tris, 300 mM NaCl, 2 mM CaCl2, pH 7.4). Bound protein 
was eluted overnight at 4°C with 20 mM Tris, 140 mM NaCl, 50 mM EDTA, pH 7.4. 
The eluted protein was then buffer exchanged into 20 mM sodium phosphate buffer pH 
7.4 (57). The purified SAP was assayed by size exclusion chromatography using a 
Superose 12 (GE Healthcare Life Sciences, Piscataway, NJ) column on an AKTA 
chromatography system (GE Healthcare Life Sciences) as previously described (57). 
Purified SAP was labeled using Alexa Fluor 647-NHS (Life Technologies) following the 
manufacturer’s protocol.  
 
Neutrophil adhesion assay, macrophage phagocytosis assay, and SAP binding to 
Zymosan A 
Neutrophils were incubated with 80 nM (10 µg/ml) of wildtype (WT) or mutated 
SAP, and their binding to human plasma fibronectin (Trevigen, Gaithersburg, MD) was 
assessed as previously described (20). To determine the effect of Fc receptor ligation on 
neutrophil adhesion, neutrophils were incubated with 5 µg/ml of either anti-FcRI 
antibody clone 10.1 (mouse IgG1, eBiosciences), anti-FcRII antibody clone Clkm-5 
(mouse IgG1, Millipore, Billerica, MA), anti-FcRII antibody clone FUN-2 (mouse 
IgG1, Biolegend), anti-FcRII antibody clone AT10 (mouse IgG1, Abcam, Cambridge, 
MA), anti-FcRIII antibody clone 3G8 (mouse IgG1, Biolegend), or a mouse IgG1 
isotype control (Biolegend). Phagocytosis of FITC-conjugated Zymosan A bio-particles 
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(Life Technologies) by macrophages was assayed as described previously (25). To 
measure the binding of SAP to Zymosan A bio-particles, we first quenched the 
fluorescence of FITC-conjugated Zymosan A with 2% Trypan blue in PBS for 20 
minutes and then incubated the quenched Zymosan A bio-particles with 240 nM (30 
µg/ml) of WT SAP or mutant SAP in 20 mM Tris, 140 mM NaCl, 2 mM CaCl2 for 1 
hour. The bio-particles were then washed, and bound SAP was detected by staining with 
anti-SAP antibody clone 5.4A (Millipore) and goat anti-mouse Alexa Fluor-647 (Life 
Technologies) on an Accuri C6 flow cytometer (BD Bioscience).  
 
SAP affinity assays and receptor expression 
FcRI and Fc common -chain (FcR) cDNA (PSI:Biology-materials repository, 
Tempe, AZ) (90, 91) were ligated into the pCMV6-AC-His vector (OriGene, Rockville, 
MD) and then transfected into HEK293 cells using jetPRIME (Polyplus, New York, 
NY) following the manufacturer’s protocol. FcRIIIb plasmid was obtained from the 
PSI:Biology-materials repository and transfected into HEK293 cells. K562 cells, which 
express FcγRIIa, were used to measure the affinity of SAP for FcγRIIa (92). The binding 
of fluorescently labeled WT SAP or mutant SAP to cells was then measured as 
previously described using an Accuri C6 flow cytometer (25). When measuring SAP 
binding to HEK293 cells expressing FcRI or FcRIIIb, mock transfected HEK293 cells 
were used to estimate the non-specific binding. K562, HEK293, FcRI+ HEK293, and 
FcRIIa+ HEK293 cells were stained for FcRI (Cone 10.1, eBiosciences), FcγRII 
(Clone FUN-2, Biolegend), and FcRIII (Clone 3G8, Biolegend) to determine the 
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expression of the indicated receptor by flow cytometry (87). Leukocytes stained for CD3 
(Biolegend), CD14 (Biolegend), CD15 (Biolegend), CD19 (Biolegend), CD45 
(Biolegend), FcRI (Clone 10.1, eBiosciences), FcRII (Clone FUN-2, Biolegend), and 
FcRIII (Clone 3G8, Biolegend) were assayed by flow cytometry to determine the 
presence of different immune cell populations as previously described (87, 88, 93). 
 
Statistical analysis 
Data was analyzed by ANOVA (with Dunnett's post test) or t-test when 
appropriate using Prism software (GraphPad software, San Diego, CA). Data were fit to 
the appropriate model of binding as determined by F-tests. Normality was tested using 
Shapiro-Wilk and D'Agostino-Pearson omnibus tests when applicable. 
 
Results 
Identification of SAP amino acids that affect neutrophil adhesion 
We previously made site-directed mutations of human SAP at amino acids that 
interact with human FcRIIa in a SAP-FcRIIa co-crystal structure (83), and observed 
that changes to these amino acids had no significant effect on the ability of SAP to 
inhibit fibrocyte differentiation (57). To better understand the interaction of SAP with 
Fcγ receptors, we compared the amino acid sequence of human SAP to the related 
pentraxin CRP. SAP and CRP have 51% sequence identity and similar crystal structures, 
but have different affinities for Fcγ receptors and different roles in the immune system 
(4, 23, 24, 83). Thus, the sequence differences can be used to identify structurally and 
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functionally significant amino acids. Of the amino acids that were different between 
SAP and CRP, we mutated only the ones that were exposed on the surface of SAP (83). 
E153, which is at the interface between SAP monomers, was also mutated in an attempt 
to destabilize the pentameric protein and introduce functional defects. We then 
expressed all the generated SAP variants in HEK293 cells. All the SAP variants eluted at 
10-12 ml from a Superose 12 size exclusion chromatography column, indicating the 
absence of aggregates larger than pentamers, and the absence of free monomers (Table 1 
and Fig. 4A). We subsequently tested the ability of these variants to decrease neutrophil 
adhesion, inhibit fibrocyte differentiation, and promote phagocytosis. In addition, we 
examined the binding of these variants to Fcγ receptors.  
We first examined the ability of our SAP variants to reduce neutrophil adhesion 
to human fibronectin. We screened 29 SAP variants for their ability to reduce neutrophil 
adhesion and then based on our preliminary data focused on 13 of the examined variants 
(data not shown). These 13 SAP variants were screened at 80 nM (10µg/mL) (Fig. 4B). 
We chose this concentration because it was close to the IC50 (67 ± 7 nM) of SAP for 
reducing neutrophil adhesion (Fig. 4C) and hence allowed us to detect both increases 
and decreases in the SAP effect on neutrophils. Following our screen, we observed that 
SAP variants E126A and Q128A had increased inhibitory effect on neutrophil adhesion 
compared to WT SAP (Fig. 4B). SAP variant K130V conversely had a significantly 
reduced inhibitory effect on neutrophil adhesion (Fig. 4B).  
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 SAP Variants 
Multimerization 
state Hill Coefficient  IC50 (nM ± SEM) 
WT SAP Pentameric 1.8      ± 0.1 2.9      ± 0. 3 
H19A Pentameric 1.8      ± 0.1 1.1      ± 0.1 
N21A Pentameric 2.2  ± 0.2 2.5 ± 0.5 
I23G Pentameric 0.9 ± 0.1 1.2 ± 0.7 
T24A Pentameric 2.6 ± 1.2 5.3 ± 1.7 
E27A Pentameric 0.7 ± 0.1 1.6 ± 0.8 
Q31A Pentameric 1.9 ± 0.2 2.9 ± 1.1 
Q55A Pentameric 1.1 ± 0.2 1.5 ± 0.5 * 
G56A Pentameric 2.1 ± 0.1 4.4 ± 2.8 
V68A Pentameric 3.8 ± 1.4 * 2.8 ± 0.5 
K87A Pentameric 1.7 ± 0.7 1.6 ± 0.8 
S101A Pentameric 0.8 ± 0.5 5.4 ± 0.2 
E126A Pentameric 0.8 ± 0.1 8.1 ± 1.0 * 
Q128A Pentameric 2.7 ± 0.3 * 2.5 ± 0.6 
P129A Pentameric 1.4 ± 0.4 2.9 ± 0.8 
K130V Pentameric 1.6 ± 0.2 1.1 ± 0.2 * 
Y140A Pentameric 3.1 ± 1.1 4.3 ± 1.3 
K143A Pentameric 16.4 ± 10.3  2.7 ± 1.1 
R146A Pentameric 1.1 ± 0.5 5.4 ± 1.4 
E153A Pentameric 3.3 ± 1.5 19.2 ± 5.7 * 
P165A Pentameric 1.1 ± 0.4 4.4 ± 0.3 
S171A Pentameric 1.5 ± 0.3 2.9 ± 0.5 
Y173A Pentameric 2.4 ± 0.2 4.9 ± 1.1 
Q174A Pentameric 1.3 ± 0.1  6.9 ± 1.2 
N189A Pentameric 1.9 ± 0.7 3.3 ± 0.2 
R193A Pentameric 3.3 ± 1.6  1.8 ± 0.9 
I23A-Q55A Pentameric 1.1 ± 0.1 1.9 ± 0.5 
I23A-K130V Pentameric 0.7 ± 0.4 13.6 ± 7.4 
Q55A-K130V Pentameric 3.3 ± 2.5 4.7 ± 3.2 
I23A-Q55A-K130V Pentameric 1.2 ± 0.3 6.6 ± 2.1  
 
Table 1: The effect of SAP variants on monocyte to fibrocyte differentiation. 
PBMCs were incubated with different concentrations of the indicated SAP variant as 
shown in Figure 2. After 5 days, the cells were stained and the fibrocyte counts for each 
SAP variant were used to estimate the IC50 and the Hill coefficient for inhibition of 
fibrocyte differentiation. Pentamerization was assessed using a Superose 12 size 
exclusion chromatography column. The SAP variants were considered pentameric if 
they eluted at 10-12 ml. Values are IC50 or Hill coefficient ± SEM, n=3-10. The data for 
SAP variants S171A, Y173A, and Q174A were taken from (21).  * indicates p < 0.05 by 
t-test when compared to the wildtype (WT) SAP.  
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Figure 4: Some SAP variants have an altered effect on neutrophil adhesion to 
human fibronectin.  
A) A representative plot indicating that both WT SAP and K87A variant are pentameric. 
B) Human neutrophils were incubated with 80 nM (10 µg/ml) of the indicated SAP 
variants. Following the initial incubation with SAP, the neutrophils were transferred to a 
fibronectin coated plate and were then activated by the addition of TNF-. After 30 
minutes, the non-adherent neutrophils were removed and the remaining cells were 
stained and counted. C) Human neutrophils were incubated with increasing 
concentrations of WT SAP to estimate the IC50 of SAP for reducing neutrophil adhesion. 
The data were fit to a sigmoidal dose response curve with variable Hill coefficient. 
Values are adherent neutrophils normalized to the TNF-α control ± SEM, n=3-7. ** 
represents p<0.01 and *** represents <0.001 by t-test. 
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Identification of SAP amino acids that affect fibrocyte differentiation 
Since SAP inhibits fibrocyte differentiation, we also screened the 29 SAP 
variants for their ability to inhibit the differentiation of monocytes into fibrocytes (Table 
1) (54, 57, 86, 87). Using PBMCs from a variety of donors, we observed 1200 to 3100 
fibrocytes per 10
5
 PBMCs. Because of this variability, fibrocyte counts were normalized 
to the no-SAP control, as described previously (57, 86, 94). WT SAP inhibited fibrocyte 
differentiation with an IC50 of 2.9 ± 0.3 nM, similar to previously published data (54, 
57). 25 out of the 29 variants tested did not significantly alter the ability of SAP to 
inhibit fibrocyte differentiation (Table 1). Compared to wildtype SAP, variants Q55A 
and K130V were more effective at inhibiting fibrocyte differentiation whereas variants 
E153A and E126A had reduced activity (Fig. 5 and Table 1). In addition, we observed 
significant changes in the Hill coefficient of SAP variants V68A and Q128A compared 
to WT SAP (Table 1). This change could be due to alterations in SAP variant binding to 
Fc receptors and/or how these variants activate the receptors. 
 
Identification of SAP amino acids that affect phagocytosis 
SAP enhances phagocytosis of pathogens and cell debris through Fcγ receptors 
(24, 25). However, the exact receptor and amino acids involved are unknown. We first 
screened the 29 SAP variants for their ability to enhance phagocytosis and then based on 
our preliminary data focused on 13 variants (data not shown). The 13 SAP variants were 
screened at 240 nM (30µg/mL, physiological concentration in the human plasma) for  
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Figure 5: Some SAP variants have an altered effect on human fibrocyte 
differentiation.  
PBMCs were incubated for 5 days in the presence of WT SAP or SAP variants. 
Compared to WT SAP, the SAP variants K130V and Q55A were more effective 
inhibitors of fibrocyte differentiation, whereas E126A and E153A had reduced activity. 
Values are fibrocyte count normalized to the no-SAP control ± SEM, n=3-5. The data 
were fit to sigmoidal dose response curves with variable Hill coefficients. The absence 
of error bars indicates that the error was smaller than the plot symbol. 
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Figure 6: Amino acids Q128 and E153 on SAP are necessary for SAP-mediated 
phagocytosis.  
A) FITC-labeled Zymosan A bio-particles were incubated in the presence of WT SAP or 
SAP variants and then added to monocyte-derived macrophages. After 1 hour, the free 
bio-particles were removed and the number of phagocytized particles was counted. The 
phagocytic index was estimated as the number of bio-particles engulfed by 100 
macrophages. Values are means of the phagocytic index normalized to the WT SAP ± 
SEM, n=3-6. B) The binding of WT, Q128A, and E153A SAP to Zymosan A was 
detected using an anti-SAP antibody and flow cytometry. Values are mean ± SEM, n=3. 
* represents p<0.05 by t-test. 
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their ability to promote phagocytosis of Zymosan A bio-particles by macrophages (Fig. 
6A). 11 of the SAP variants examined did not significantly alter the ability of SAP to 
enhance phagocytosis (Fig. 6A). Compared to WT SAP, SAP variants Q128A and 
E153A had significantly reduced ability to promote phagocytosis by macrophages (Fig. 
6A). We then measured the binding of WT, Q128A and E153A SAP to Zymosan A bio-
particles to determine if these SAP variants had deficiencies in binding the bio-particles. 
Compared to WT SAP, we found no statistically significant differences in the binding of 
Q128A or E153A to Zymosan A (Fig. 6B). Together, this indicates that SAP variants 
Q128A and E153A have defects in binding and/or activating Fcγ receptors to promote 
phagocytosis of Zymosan A. 
 
SAP binds to endogenous FcRI and FcRIIa on immune cells 
Much of the work done on SAP binding to Fcγ receptors has focused on SAP 
binding to recombinant Fcγ receptors or to receptors expressed on non-human cells such 
as COS-7 and NIH-3T3 (23, 25, 83). This is problematic because the affinity of Fcγ 
receptors for their ligands is sensitive to the receptor glycosylation state and the presence 
of intracellular signaling proteins (26, 95-97). Therefore to identify functionally 
significant receptors in the SAP response, we examined the binding of SAP to 
endogenous Fcγ receptors on human immune cells and to receptors expressed on the 
human-derived cell line HEK293. We used fluorescently labeled WT SAP (SAP-f) to 
measure the binding to different peripheral blood cell populations as identified by their 
flow characteristics and receptor expression (Fig. S1). We tested the activity of SAP-f on  
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Figure 7: Alexa Fluor 647-labeled SAP (SAP-f) binds to monocytes and neutrophils.  
A) SAP-f was incubated with isolated leukocytes and then subjected to flow cytometry. 
Neutrophils, monocytes, and lymphocytes were identified based on forward scatter and 
side scatter as in Figure S2. Autofluorescence values were subtracted from the total 
binding values. Curves are fits of the resulting data to models of one-site binding with 
variable Hill coefficient. B) WT HEK293 cells and HEK293 cells expressing Fc
RIIIb were incubated with 20 µg/ml of human IgG-Alexa Fluor 488 and then subjected 
to flow cytometry to determine if the expressed receptor is functional and therefore binds 
IgG. Values are mean ± SEM, n=3. * represents p<0.05 by t-test. C) HEK293 cells 
expressing FcRIIIb were incubated with SAP-f and then subjected to flow cytometry to 
measure SAP binding. Mock transfected cells were used to estimate the non-specific 
binding, which was then subtracted from the total binding. Values are adjusted median 
fluorescence intensity ± SEM, n=3. The data were fit to a line. The absence of error bars 
indicates that the error was smaller than the plot symbol. 
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neutrophils, monocytes, and macrophages and observed no functional defects compared 
to unlabeled SAP (Fig. S2). When SAP-f was incubated with leukocytes, we observed 
no binding to the lymphocyte population (Fig. 7A). Since B cells (~5 % of lymphocytes) 
express FcRIIb (84), and NK cells (~5-10% of lymphocytes) express FcRIIIa (84), this 
suggests that SAP does not bind to these receptors under our experimental conditions. 
However, SAP-f did bind to monocytes and neutrophils (Fig. 7A). Monocytes express 
FcRI, FcRIIa, and some FcRIIIa (Fig. S1) (20, 88). This indicates that SAP could be 
binding to any or all of the Fc receptors on monocytes. As NK cells express FcRIIIa, 
and we did not detect binding of SAP-f to NK cells, this suggests that SAP binds to 
FcRI and/or FcRIIa on monocytes. Neutrophils express FcRIIa and FcRIIIb (Fig. 
S1) (20, 88). When we incubated SAP-f with FcRIIIb+ HEK293 cells, we did not detect 
any appreciable binding although the receptor was functional as determined by human 
IgG binding (Fig. 7B and C and Fig. S3). This then suggests that SAP binds to FcRIIa 
on neutrophils. We observed more SAP biding to monocytes than to neutrophils, and we 
hypothesize that this is likely due to the presence of FcRI on monocytes (Fig. 7A). 
Together, our data indicates that SAP-f binds to endogenous FcRI and FcRIIa on 
monocytes and neutrophils but not to FcRIIb, FcRIIIa, and FcRIIIb (Fig. 7). 
 
SAP binds to FcRI and FcRIIa on HEK293 cells 
Following our initial binding assays using human immune cells, we investigated 
the binding of our SAP variants to FcRI and FcRIIa. Of the 29 SAP variants, we chose 
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6 that had altered functions as measured by neutrophil adhesion assays, fibrocyte 
differentiation assays, and macrophage phagocytosis assays. The 6 SAP variants were 
fluorescently labeled and then incubated with K562 cells to measure the binding to 
FcRIIa. The only known receptor that binds SAP on the surface of K562 cells is  
FcRIIa ((92) and Fig. S3). WT SAP bound to FcRIIa with a Kd of 19.7 ± 3.4 nM (Fig. 
8A and Table 2). Previous measurements of the Kd for SAP binding to FcRIIa range 
from 0.29 nM to 1.4 µM (23, 25, 83). As previously described, these inconsistencies are 
most likely caused by the method of receptor expression and how the Kd was estimated 
(26). Of the 6 SAP variants tested, compared to WT SAP, E126A, Q128A, and K130V 
had significant differences in their binding to FcRIIa (Fig. 8A and Table 2). These 
changes in affinity correlate with the ability of these SAP variants to reduce neutrophil 
adhesion. Variants E126A and Q128A have a higher affinity for FcRIIa and have an 
increased inhibitory effect on neutrophil adhesion (Table 2 and Fig. 7). Conversely, 
variant K130V has a decreased affinity for FcRIIa and has a reduced inhibitory effect 
on neutrophil adhesion to fibronectin (Table 2 and Fig. 7). In addition, variant E126A 
has a Hill coefficient of 3.3 ± 0.5, indicating cooperativity in SAP E126A-FcRIIa 
binding. This cooperatively is absent from the other SAP variants as their Hill 
coefficient is not significantly different from the 1.2 ± 0.2 we measured for WT SAP. 
One possible explanation for this increased Hill coefficient is self-aggregation of SAP 
E126A following binding to cells. This would then manifest as an increase in the 
maximal binding (Bmax) of SAP E126A to cells. However, the SAP E126A Bmax was  
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Figure 8: SAP variant binding to FcRIIa and FcRI.  
A) K562 cells, which express FcRIIa, were incubated with fluorescently-labeled SAP 
variants. The cells were then washed and the binding of the labeled SAP to the cells was 
measured by flow cytometry. B) HEK293 cells expressing FcRI were incubated with 
fluorescently-labeled SAP variants and then binding was measured by flow cytometry. 
Mock transfected cells were used to estimate the non-specific binding. Median 
fluorescence intensity values were normalized to the intensity value of the highest SAP 
concentration. Values are normalized mean ± SEM, n=3-5. Curves are fits to models of 
one-site binding with variable Hill coefficient. The absence of error bars indicates that 
the error was smaller than the plot symbol. 
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SAP 
Variants 
FcRI Kd 
(nM ± SEM) 
Hill coefficient 
 
FcRIIa Kd  
(nM ± SEM) 
Hill coefficient 
 
WT SAP 4.6 ± 0.8 2.1 ± 0.6 19.7 ± 3.4 1.2 ± 0.2 
I23G 9.8 ± 5.8 1.1 ± 0.4 25.2 ± 9.8 1.5 ± 0.4 
Q55A 2.6 ± 0.1 *** 6.7 ± 0.2 *** 22.3 ± 3.3 1.7 ± 0.2 
E126A 36.9 ± 2.8*** 0.9 ± 0.1 11.9 ± 0.6 * 3.3 ± 0.5 * 
Q128A 24.7 ± 6.0 *   0.9 ± 0.1* 11.9 ± 2.1 * 2.3 ± 0.6 
K130V 4.5 ± 0.7 3.7 ± 1.9 43.7 ± 8.7 * 1.4 ± 0.4 
E153A 5.3 ± 0.6 3.2 ± 0.9 27.8 ± 1.4 4.7 ± 0.9 
 
Table 2: Binding of SAP variants to FcRI and FcRIIa.  
HEK293 cells expressing FcRI were incubated with Alexa Fluor 647-labeled SAP 
variants. The cells were then washed and the binding of the labeled SAP to the cells was 
measured by flow cytometry. Mock transfected cells were used to estimate the non-
specific binding. K562 cells were used to measure the binding of SAP variants to 
FcRIIa. Values are mean ± SEM, n=3-6. * indicates p < 0.05 and *** indicates p < 
0.001 by t-test when compared to the corresponding wildtype (WT) control. 
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69.7 ± 10.8 % of WT SAP (mean ± SEM, p not significant by t-test), indicating that SAP 
E126A was not aggregating on the surface of cells. To measure the binding of our 6 SAP 
variants to FcRI, we used FcRI+ HEK293 cells (Fig. S3). The FcRI+ HEK293 cells 
were co-transfected with FcR, as this intracellular protein is necessary for FcRI 
localization to the cell membrane (98). The mock transfected cells were used to estimate 
the non-specific binding (Fig. 9). WT SAP bound to FcRI with a Kd of 4.6 ± 0.8 nM 
and a Hill coefficient of 2.1 ± 0.6 (Table 2). This affinity matches the previously 
published Kd of 4.3 nM (23). The Hill coefficient of greater than 1 for the SAP-FcRI 
interaction suggests cooperativity, and could indicate FcRI receptor-receptor 
interactions. Compared to WT SAP, variants Q55A, E126A, and Q128A had significant 
changes in their affinity for FcRI (Fig. 8B and Table 2). However, we did not observe 
any significant changes in the Bmax values of Q55A (105 ± 36.7 % of WT SAP), E126A 
(123.9 ± 45.2), and E128A (110.9 ± 14.4) when binding to FcRI. All the changes in 
affinity observed for Q55A, E126A, and E128A correlate with the ability of these 
variants to inhibit fibrocyte differentiation. Variant Q55A has a higher affinity for FcRI 
and increased inhibitory effect on fibrocyte differentiation (Table 1 and Table 2). SAP 
variant E126A has decreased affinity for FcRI and has reduced inhibitory effect on 
fibrocyte differentiation (Table 1 and Table 2). The decrease in affinity of Q128A 
variant for FcRI does not alter the IC50 of SAP for fibrocyte differentiation but it does 
abrogate enhancement of phagocytosis by macrophages (Fig. 9A and Table 1). 
Additionally, the decrease in affinity of SAP Q128A for FcRI significantly increases  
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Figure 9: Estimating the specific binding of WT SAP to FcRI.  
HEK293 cells expressing FcRI were incubated with Alexa Fluor 647-labeled WT SAP 
(SAP-f) as in Table 2. The cells were then washed and the binding of SAP-f to the cells 
was measured by flow cytometry. The specific binding was estimated by subtracting the 
binding of SAP-f to mock transfected cells from FcRI expressing cells. The values were 
normalized to the median fluorescence intensity of SAP total binding at 32 nM. Values 
are mean ± SEM, n=3. The absence of error bars indicates that the error was smaller than 
the plot symbol. 
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the Hill coefficient from 1.8 ± 0.1 in WT SAP to 2.7 ± 0.3 in our fibrocyte 
differentiation assay (Table 1). This indicates that although the IC50 is not altered by this 
mutation, Q128 still plays a role in inhibition of fibrocyte differentiation by SAP. 
Together, our data indicates that SAP binds to FcRIIa on neutrophils to reduce 
neutrophil adhesion and to FcRI on monocytes to inhibit fibrocyte differentiation. 
 
FcRIIa and FcRIIIb ligation reduces neutrophil adhesion 
Our analysis of SAP variant binding to FcRI and FcRIIa indicates the 
significance of FcRIIa in SAP reduction of neutrophil adhesion. To corroborate this 
finding, we investigated the effect of antibody-mediated ligation of FcRI, FcRIIa, and 
FcRIIIb on neutrophil adhesion. Mouse IgG1 and the anti-FcRI antibody clone 10.1 
had no effect on neutrophil adhesion (Fig. 10). However, 2 of 3 anti-FcRIIa antibodies 
and an anti-FcRIIIb antibody tested decreased neutrophil adhesion (Fig. 10). The anti-
FcRII antibody clone AT10 is a blocking antibody and reduces IgG binding to FcRII, 
but in our assay it had no effect on neutrophil adhesion. Together, this indicates that SAP 
binds FcRIIa to decrease neutrophil adhesion, and that FcRIIIb ligation by antibodies 
can also reduce neutrophil adhesion to fibronectin. 
 
Blocking FcRI using antibodies abrogates SAP inhibition of fibrocyte differentiation  
SAP variant binding to FcRI and the functional data on fibrocyte differentiation 
suggests a critical role for FcRI in mediating the SAP effect on fibrocytes. To test this  
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Figure 10: Ligating FcRIIa and FcRIIIb by antibodies decreases neutrophil 
adhesion.  
Neutrophils were incubated with the indicated anti-Fc receptor antibodies to assess the 
effect of Fc receptor ligation on neutrophil adhesion to fibronectin as described in 
Figure 4. Values are adherent neutrophils normalized to the TNF-α control, mean ± 
SEM, n=3. * indicates p<0.05 by t-test. 
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Figure 11: FcRI blocking antibodies reduce the effect of SAP on fibrocyte 
differentiation.  
PBMCs were incubated with F(ab′)2 fragments of anti-Fc receptor antibodies in the 
presence or absence of WT SAP to determine their effect on SAP-mediated inhibition of 
fibrocyte differentiation. Values are fibrocyte count normalized to the control ± SEM, 
n=4. * represent p <0.05 by t-test; n.s. indicates not significant. 
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hypothesis, we incubated PBMCs with F(ab′)2 fragments of anti-FcRI, anti-FcRII, and 
anti-FcRIII antibodies in the presence or absence of WT SAP. The anti-FcRII and anti- 
FcRIII antibodies used in this experiment do not discriminate between the different 
FcRII or FcRIII isoforms (99). However, they do block IgG binding to all FcRII or 
FcRIII receptors (99). Mouse IgG1, anti-FcRII, and anti-FcRIII antibodies had no 
effect on the inhibitory effect of SAP on fibrocyte differentiation (Fig. 11). However, the 
F(ab′)2 fragment of anti-FcRI antibody clone 10.1 reduced the ability of SAP to inhibit 
fibrocyte differentiation (Fig. 11). This indicates that SAP binds to FcRI to inhibit 
fibrocyte differentiation.  
 
Identification of a novel Fc receptor binding site on SAP 
Following our functional assays, we mapped all the mutated amino acids onto the 
SAP structure (Fig. 12A). Excluding amino acid E153, all the functionally significant 
amino acids form a distinct binding site on the surface of SAP (Fig. 12B and 12C). This 
novel binding site is different from the previously identified FcγRIIa binding site (Fig. 
12B and (25)). The position of this novel binding site on SAP may allow for the binding 
of multiple Fc receptors. 
 
Discussion 
The pentraxin Serum Amyloid P (SAP) is an anti-fibrotic agent that inhibits 
aberrant scar tissue formation by regulating neutrophils, monocytes, and macrophages 
(20, 23, 25, 64, 100). All SAP functions appear to be mediated partly through Fc  
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Figure 12: Identification of a novel Fcγ receptor binding site on SAP.  
A) Mutated amino acid residues are indicated by molecular surface representation (gray) 
on the SAP structure. B) The functionally significant amino acid residues (green) are 
distinct from the previously identified FcRIIa binding site (red). C) When E153 is 
excluded; the remaining functionally significant amino acid residues form a distinct 
binding site. The yellow spheres represent the two calcium ions bound to SAP. 
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receptors (23, 57, 58). As there are multiple Fc receptors on neutrophils, monocytes, 
and macrophages, we determined how each receptor contributed to different SAP 
function. We found through site-directed mutagenesis that SAP binds to FcRI on 
monocytes to inhibit fibrocyte differentiation and to FcRIIa on neutrophils to reduce 
adhesion to fibronectin. In addition, we identified a novel Fcreceptor binding site on 
SAP. 
Mutations in SAP that affect binding to FcRIIa significantly change the ability 
of SAP to reduce neutrophil adhesion to fibronectin. Similar to SAP, ligating FcRIIa by 
anti-FcRII antibodies decreases neutrophil adhesion. This suggests that SAP binds to 
FcRIIa to decrease cell adhesion. The activation of FcRIIa results in the 
phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) in the 
cytosolic region of this receptor (29). ITAM phosphorylation is implicated in inside-out 
signaling and regulation of adhesion molecules (29). This then suggests that FcRIIa 
activation can reduce adhesion of neutrophils to fibronectin by regulating adhesion 
molecules on neutrophils. Additionally, ligating FcRIIIb by an anti-FcRIII antibody 
reduces neutrophil adhesion to fibronectin, suggesting that ligands of FcRIIIb such as 
immunoglobulin could also regulate neutrophil adhesion to fibronectin. 
Mutations in SAP that affect binding to FcRI significantly alter the ability of 
SAP to inhibit fibrocyte differentiation. In addition, blocking FcRI with an IgG 
blocking antibody reduces the SAP effect on fibrocyte differentiation. Together, this 
suggests that although there are multiple Fc receptors on monocytes, SAP activates 
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FcRI to inhibit fibrocyte differentiation. This is in agreement with our previous results 
where we observed that siRNA knock down of FcRI in humans results in decreased 
inhibitory effect of SAP on fibrocyte differentiation (57), and that cross-linking FcRI 
with antibodies can mimic the inhibitory effect of SAP on fibrocyte differentiation (101). 
Here, we have identified a FcRI binding site on each SAP monomer, suggesting that 
SAP can cross-link multiple Fc receptors (Fig. 12). Together, this suggests a role for 
FcRI cross-linking in SAP inhibition of fibrocyte differentiation. 
SAP appears to promote phagocytosis of bio-particles such as Zymosan A 
through FcRI (Table 2 and (24). However, not all SAP variants with alteration in FcRI 
binding have defects in phagocytosis. For instance, variant E126A has a ~ 10 fold 
reduction in affinity for FcRI and defects in inhibiting fibrocyte differentiation, but has 
no deficiencies in promoting phagocytosis. This suggests that a SAP opsonized bio-
particle activates FcRI to promote phagocytosis in a manner that is distinct from how 
SAP activates FcRI to inhibit fibrocyte formation. This is supported by the fact that 
FcRI mediated phagocytosis is Syk-kinase dependent but inhibition of fibrocyte 
differentiation by SAP is Syk-kinase independent (58, 102-104). It is also possible that 
SAP binding to FcRI is sufficient to promote phagocytosis irrespective of changes in 
SAP-FcRI affinity. Alternatively, it is feasible that Q128A and E153A modulate 
Zymosan A phagocytosis by altering macrophage activation. However, SAP opsonized 
Zymosan A particles were incubated with macrophages for a short time (60 minutes), 
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which would not allow for significant alteration in macrophage activation and 
phenotype. 
In surface plasmon resonance experiments, SAP binds to all of the Fcreceptors 
(23, 83). However, we observed that SAP only binds to endogenous FcRI and FcRIIa 
on immune cells. This inconsistency can be explained by the differences in the 
glycosylation state of the receptors and/or the lack of some intracellular signaling 
components (26). FcRIIIa is a highly glycosylated receptor in humans. Modifying 
FcRIIIa glycosylation changes its affinity for IgG and perhaps SAP (26). FcRI and 
FcRIIIa in humans interact with an intracellular protein called Fc common -chain 
(FcR) (26, 98). The absence of FcRalters the affinity of FcRI and FcRIIIa for IgG in 
humans (26, 98). This can potentially alter SAP binding to FcRI and FcRIIIa. 
Together, this suggests that the SAP affinity for Fc receptors is dependent on the 
modification of these Fc receptors and the interactions they make prior to binding SAP.  
Our findings indicate that it is possible to mimic specific SAP functions by 
targeting particular Fc receptors (Fig. 13). For instance, activation of FcRIIa by 
antibodies or small molecules could be used to decrease neutrophil adhesion and hence 
reduce neutrophil accumulation in lungs of patients suffering from acute respiratory 
distress syndrome or cystic fibrosis. Similarly, blocking SAP binding to FcRI might 
promote fibrocyte differentiation and wound healing. In addition, our results suggest that 
altering the SAP sequence could improve its ability to inhibit fibrocyte differentiation 
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and/or reduce neutrophil adhesion. This could lead to the development of a more potent 
SAP anti-fibrotic.  
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Figure 13: A model of the SAP effect on monocytes and neutrophils. 
SAP cross-links FcRI to inhibit fibrocyte differentiation in a Syk kinase independent 
manner. SAP also binds FcRI to promote phagocytosis of zymosan A by macrophages. 
However, this pathway is Syk kinase dependent. SAP binds to FcRIIa which then 
phosphorylates the ITAM domain of FcRIIa. This then regulates adhesion molecules on 
the surface of neutrophils and decrease neutrophil adhesion.  
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CHAPTER III 
DC-SIGN MEDIATES THE DIFFERENTIAL EFFECTS OF PENTRAXINS ON THE 
INNATE IMMUNE SYSTEM 
Summary 
Fibrosis is caused by scar tissue formation in internal organs and is associated 
with 45% of deaths in the U.S. Two closely related human serum proteins, Serum 
Amyloid P (SAP) and C-reactive protein (CRP), strongly affect fibrosis. In multiple 
animal models, and in Phase 1 and Phase 2 clinical trials, SAP suppresses several 
aspects of the innate immune system to reduce fibrosis, whereas CRP appears to 
potentiate fibrosis. However, SAP and CRP bind the same Fcγ receptors (FcγR) with 
similar affinities, and why SAP and CRP have opposing effects is unknown. Here we 
report that a glycosylation on SAP that is not present on CRP binds the receptor DC-
SIGN (SIGN-R1) to suppress the innate immune system, and that FcγR are not 
necessary for SAP function. A polycyclic aminothiazole DC-SIGN ligand and anti-DC-
SIGN antibodies mimic SAP effects in vitro. In mice, the aminothiazole reduces 
neutrophil accumulation in a model of acute lung inflammation, and at 0.001 mg/kg 
alleviates pulmonary fibrosis by increasing levels of the immunosuppressant IL-10. DC-
SIGN (SIGN-R1) is present on mouse lung epithelial cells, and SAP and the 
aminothiazole potentiate IL-10 production from these cells. Our data suggest that SAP 
activates DC-SIGN to regulate the innate immune system differently from CRP, and that 
the aminothiazole and anti-DC-SIGN antibodies are potential therapeutics for fibrosis. 
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Introduction 
Fibrosing diseases such scleroderma, pulmonary fibrosis, and renal fibrosis are 
caused by aberrant scar tissue formation in internal organs and are associated with 45% 
of deaths in the U.S. (73). At a fibrotic lesion, monocytes leave the blood, enter the 
tissue, and differentiate into cells such as macrophages and fibrocytes (45). Fibrocytes 
and macrophages then secrete extracellular matrix (ECM) proteins, ECM modifying 
enzymes, and/or cytokines such as IL-4 to promote scar tissue formation and fibrosis 
(71, 82, 105, 106). 
Pentraxins are a family of highly conserved secreted proteins that have a 
profound effect on the development of fibrosis and regulation of the innate immune 
system (10, 11, 107). The pentraxin Serum Amyloid P (SAP) reduces neutrophil 
activation and recruitment (20, 108), inhibits the differentiation of monocytes into 
fibroblast-like cells called fibrocytes(54, 56, 108), and promotes IL-10-secreting 
macrophages (23, 64, 70). In animal models and two human trials (23, 56, 59, 71, 78, 
109), injections of SAP decrease fibrosis indicating that SAP has a dominant effect on a 
disease that is mediated in part by the innate immune system. Conversely, the closely-
related pentraxin C-reactive protein (CRP) has a pro-inflammatory effect and promotes 
fibrosis (110-112).  Human serum CRP levels increase up to a thousand fold during 
infection and inflammation (113), and elevated serum CRP is the best biomarker for 
inflammatory diseases (10). However, under some conditions, CRP decreases 
inflammation, indicating that much remains to be understood about this molecule (10, 
114). In contrast to SAP and CRP, which are produced by hepatocytes, Pentraxin 3 
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(PTX3) is produced by macrophages, neutrophils, endothelial cells, epithelial cells, and 
fibroblasts (3). PTX3 is associated with inflammation in humans, but in mice appears to 
be pro-inflammatory in some models and limits inflammation in other models (115). 
Despite the strong effects of pentraxins on the innate immune system and fibrosis (10, 
107), little is known about their mechanism of action. For instance, pentraxins such as 
SAP and CRP appear to bind the same Fc receptors (FcR) with similar affinities (11, 
83, 108), but they generally have opposite effects. What causes this functional difference 
is not known.  
Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN/CD209) is a C-type lectin found on dendritic cells, macrophages, and 
monocytes (116, 117). DC-SIGN mainly binds to mannosylated and fucosylated proteins 
(116, 117). In humans, there is a single DC-SIGN receptor, whereas mice have eight 
DC-SIGN orthologs called SIGN-R1-8 (118). SIGN-R1 most closely resembles DC-
SIGN (118). DC-SIGN and SIGN-R1 also bind sialylated proteins such as IgG (sIgG) 
(117). Both sIgGs and SAP have α(26)-linked terminal sialic acids on the protein 
surface, and both sIgGs and SAP alleviate inflammation in mice (107, 117, 119).  
In this report, we show that in absence of all the FcR, neutrophils, monocytes 
and macrophages still respond to SAP, indicating that SAP uses other receptors. For 
SAP, we show that one of the other receptors is DC-SIGN. A small-molecule DC-SIGN 
ligand mimics the effects of SAP. This ligand shows efficacy in murine models of acute 
lung inflammation and pulmonary fibrosis. In contrast to SAP, we find that CRP requires 
-10 secretion from macrophages, but not to 
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increase ICAM-I
+
 macrophages. This suggests that there are additional CRP receptors 
that regulate macrophage polarization. Our findings suggest the presence of a novel 
pentraxin target that accounts for some of the functional difference between SAP and 
CRP, and which might be useful as a therapeutic target to regulate the innate immune 
system. 
 
Methods 
Antibodies and reagents 
Mouse anti-human CD209 antibody clone H200 was obtained from Santa Cruz 
Biotechnology (Dallas, TX). Mouse anti-human CD209, CD163, and ICAM-I 
antibodies, anti-mouse CD206, ICAM-I, CD11b, Ly6G, CD45, and rat IgG1 isotype 
control antibodies, and biotinylated IL-10 (JES5-16E3) were from Biolegend (San 
Diego, CA). Anti-mouse CD11c was from MBL (Woburn, MA). Anti-mouse SIGN-R1 
(22D1) and Armenian hamster isotype control were from eBioscience (San Diego, CA). 
Anti-mouse Epcam-1 antibody was from Abcam (Cambridge, MA). Anti-rat Dylight 488 
and anti-Armenian hamster biotin-conjugated antibodies were from Novus (Littleton, 
CO). Alexa Fluor 488-anti-rabbit antibodies and IgG-free albumin were from Jackson 
ImmunoResearch (West Grove, PA). Streptavidin-Alexa Fluor 647, Alamar Blue cell 
viability reagent, and Alexa Fluor 647-NHS were from Life Technologies (Grand Island, 
NY). Human GM-CSF, mouse M-CSF, and mouse IL-13 were from Biolegend Inc. 
Sambucus Nigra lectin, streptavidin-alkaline phosphatase, and Vector Red alkaline 
phosphatase substrate kits were from Vector (Burlingame, CA). The CRP cDNA 
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expression plasmid was a kind gift from Dr. Jeff Crawford (Baylor College of Medicine, 
Houston, TX) and the DC-SIGN cDNA expression plasmid was from the NIH AIDS 
reagent program (Germantown, MD). SAP and bleomycin were from EMD Millipore 
(Billerica, MA). CRP was from Fitzgerald Industries (North Acton, MA) and PTX3 from 
R&D systems (Minneapolis, MN). Neuraminidase (Cat # N2876) and DMSO were from 
Sigma-Aldrich (St. Louis, MO). Compound 1 (Cat#5931866) was purchased from 
ChemBridge (San Diego, CA).  
 
Mouse strains 
C57/BL6 and IL-10-null mice (120) were obtained from Jackson laboratories 
(Bar Harbor, ME). FcR quad-null (121) and SIGN-R1-null (117) mice were a kind gift 
from Dr. Jeffery Ravetch (Rockefeller University, New York, NY). All animals were 
used in accordance with National Institutes of Health guidelines and with a protocol 
approved by the Texas A&M University Institutional Animal Care and Use Committee. 
 
Fibrocyte differentiation assay 
Human blood was collected into heparin tubes (BD Bioscience, San Jose, CA) 
from adult volunteers who gave written consent and with specific approval from the 
Texas A&M University human subjects Institutional Review Board. PBMCs were then 
isolated and cultured to examine human fibrocyte differentiation as described previously 
(108). Mouse spleen cells were isolated and cultured to assess murine fibrocyte 
differentiation as previously described (94).  
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Macrophage polarization assay 
Cells were cultured at 37˚C in a humidified incubator with 5% CO2. Human 
monocytes were differentiated into macrophages in 200 µl of RPMI-1640 (Lonza, Basel, 
Switzerland)/10% fetal calf serum (FCS, Seradigm, Randor,PA) for 6 days  at a 
concentration of 0.5x10
6
 cells/ml in a well of an 8 well slide (EMD Millipore). The 
medium was then replaced with fresh serum-free RPMI-1640 (supplemented with 10 
mM HEPES, 2 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and ITS-3, 
all from  Sigma-Aldrich), containing 3 µg/ml of the indicated pentraxin, 1 µg/ml of the 
indicated antibody, or 10 pg/ml of compound 1 for 3 days. Subsequently, the cells were 
dried, fixed and stained as previously described (88). Mouse tibias and femurs were 
flushed with RPMI-1640 and the cells were washed 3x in PBS. The cells were then 
resuspended in RPMI-1640/ 10% FCS and 200 µl of 5x10
5 
cells/ml was incubated in 
each well of an 8 well slide (EMD Millipore). After 1 hour, the medium and non-
adherent cells were removed and replaced with fresh RPMI-1640/ 10% FCS/ 10 ng/ml 
GM-CSF. On day 7, the medium was replaced with serum-free RPMI-1640 containing 
10 µg/ml of the indicated pentraxin. After 3 days, cells were dried, fixed and stained.  
 
Recombinant protein expression 
The cDNA for human CRP was mutated at residue 32 using a QuickChange II 
Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) and the primer 5’ 
AAGGCGCGCCATGGAGAAGCTGTTG 3’. CRP cDNA was inserted into a pCMV6-
AC-His vector (Origene, Rockville, MD) and then expressed in HEK293 cells (Life 
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Technologies, Grand Island, NY) as previously described (108). CRP and glycosylated 
CRP were purified using immobilized p-aminophenyl phosphoryl choline beads 
(Thermo Fisher scientific, Walthan, MA) following the manufacturer’s protocol. 
 
SDS-PAGE and western blots 
Proteins were diluted in 20 mM sodium phosphate, pH 7.4 to a concentration of 
40 µg/ml and then analyzed by SDS-PAGE gels as described previously (54). For 
Western blotting, proteins from gels were transferred to polyvinylidene difluoride 
membranes (Immobilon P; Millipore, Bedford, MA) in Tris/glycine/SDS buffer 
containing 20% methanol following the manufacturer’s protocol. Filters were blocked 
for 30 minutes at room temperature in Carbo-Free Blocking Solution (Vector). 
Membranes were then incubated in PBS containing 10 µg/ml of Biotinylated Sambucus 
Nigra Lectin (Vector ) for 30 minutes at room temperature to detect α (26)-linked 
terminal sialic acids following the manufacturer’s protocol. Vectastain Elite ABC 
peroxidase kits (Vector) were used to detect the biotinylated lectin following the 
manufacturer’s protocol. We then used Clarity Western ECL chemiluminescence 
substrate (Bio-Rad, Hercules, CA) to visualize the peroxidase with a ChemiDoc XRS+ 
imager (Bio-Rad). 
 
SAP desialylation 
SAP (125 KDa) was incubated with neuraminidase (SigmaAldrich) for 2 days at 
37°C following the manufacturer’s protocol. The desialylated SAP (SAP (NA)) was then 
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buffer exchanged to 20 mM Tris, pH 7.4 using a 100 KDa filter (EMD Millipore) to 
remove the 60 kDa neuraminidase. 
 
DC-SIGN binding  
The DC-SIGN cDNA expression plasmid was transfected into HEK293 cells 
(Life Technologies) using Lipofectamine 3000 (SigmaAldrich) following the 
manufacturer’s protocol. After 3 days, the transfected cells were washed twice in 20 mM 
Tris, 140 mM NaCl, 2mM CaCl2, pH 7.4 and then incubated with Alexa Fluor 647 (Life 
Technologies) labeled SAP or SAP (NA) in binding buffer (PBS/ 1 mM MgCl2/ 1 mM 
CaCl2/ 1% IgG-free albumin) at 4°C. After 1 hour, cells were washed 3x in ice cold 
binding buffer and fluorescence of the cells was measured by flow cytometry as 
previously described (108). Mock transfected cells were used to estimate the non-
specific binding. 
 
Neutrophil adhesion assay 
Human and murine neutrophils were isolated from blood and adhesion assays 
were performed as described previously (20).  
 
Mouse models of acute lung inflammation and fibrosis 
C57BL/6 mice (Jackson laboratories) were given an oropharyngeal instillation of 
3U/kg of bleomycin (EMD Millipore) to induce acute inflammation and neutrophil 
recruitment as described previously (20, 89). Pulmonary fibrosis was induced in mice by 
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instillation of 3U/Kg of bleomycin as described previously (122). Briefly, on day 0 mice 
were given bleomycin instillation (50µl) or saline (50µl). Mice were then injected with 
vehicle control (48µl PBS, 2 µl DMSO), SAP (50µg of SAP in 50µl of PBS), or 
compound 1 (48µl PBS, 2 µl compound 1 in DMSO) at the indicated dose on days 1-2 
for acute lung inflammation and days 1-20 for pulmonary fibrosis. On day 3 for the 
acute lung inflammation model and day 21 for pulmonary fibrosis model, mice were 
euthanized and the blood, bronchoalveolar lavage fluid (BAL), and the lungs were 
collected.  
 
Immunohistochemistry and immunofluorescence  
BAL cells and lungs were fixed and stained as previously described (56, 88). 
Immunofluorescence images were acquired with a FluorView FV1000 Confocal 
Microscope (Olympus, Center valley, PA). 
 
PicroSirius red staining 
PicroSirius red staining was performed as described previously (56).  
 
Cell viability assay 
Cell viability was assessed with Alamar Blue cell viability reagent (Life 
Technologies) following the manufacturer’s protocol. 
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Statistical analysis 
Data were analyzed by ANOVA (with Holm-Bonferroni posttest) or t-test when 
appropriate using Prism software (GraphPad, San Diego, CA). Statistical significance 
was defined as p < 0.05. Data were fit to the appropriate model of binding as determined 
by F-tests. 
 
Results 
Fc receptors do not mediate many of SAP and CRP effects on the innate immune system 
SAP and CRP both bind Fc receptors (FcR), but have different effects on the 
innate immune system (83, 108). To determine the role of FcR in SAP and CRP 
function, we examined the effect of these proteins on mouse cells lacking all known 
FcR (FcR quad KO). As previously observed (20, 108), SAP and CRP decreased the 
adhesion of C57BL/6 neutrophils to fibronectin (Fig. 14A). When added to FcR quad 
KO neutrophils, SAP but not CRP, significantly reduced neutrophil adhesion to 
fibronectin (Fig. 14A).  
In addition to reducing neutrophil adhesion, SAP inhibits the differentiation of 
monocytes into fibroblast-like cells called fibrocytes (54, 108) (Fig. 14B). In the absence 
of FcR, SAP reduced but could not completely inhibit fibrocyte differentiation (Fig. 
14B). As previously observed (54), CRP had no effect on fibrocyte differentiation (Fig. 
14C). The absence of FcR did not alter this (Fig. 14C).  
SAP increases the expression of CD206 (64, 88) on macrophages (Fig. 14D). 
CRP, however, primarily promotes the inflammatory M1-like phenotype (110) and 
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increased ICAM-I
+
 macrophages (Fig. 14E). Both SAP and CRP were able to polarize 
FcR quad KO macrophages as determined by CD206 and ICAM-I expression (Fig. 14, 
D and E). SAP also increased IL-10 secretion from C57BL/6 and FcR quad KO 
macrophages (Fig. 14F). In contrast, CRP increased IL-10 secretion from C57BL/6 
macrophages but not the FcR quad KO cells (Fig. 14F). PTX3 uses the FcR to 
potentiate fibrocyte differentiation (Pilling et al, manuscript submitted). However in the 
absence of the FcR, PTX3 was able to decrease neutrophil adhesion and alter 
macrophage phenotype, although the PTX3-induced IL-10 secretion by macrophages 
was absent (Fig. S4). These results indicate that SAP does not require the FcR to reduce 
neutrophil adhesion, inhibit fibrocyte differentiation, and polarize macrophages. This 
suggests the presence of additional SAP receptors. Conversely, CRP requires the FcR to 
reduce neutrophil adhesion and promote IL-10 secretion by macrophages, but not to 
increase ICAM-I
+
 macrophages. This suggests that some aspects of the CRP effect on 
macrophages is mediated by an unknown receptor. 
 
SAP glycosylation mediates many of the SAP effects on the innate immune system 
CRP has sequence and structural similarity to SAP, and like SAP binds FcR (10, 
107). However, SAP and CRP have different effects on monocyte and macrophage 
differentiation; for instance while SAP inhibits fibrocyte differentiation (56, 108) and 
promotes IL-10 secreting macrophages (64, 71), CRP has no effect on fibrocyte 
differentiation (54) and promotes pro-inflammatory macrophages (110). One possible  
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Figure 14: Fc receptors are necessary for some but not all effects of SAP and CRP 
on neutrophils, monocytes, and macrophages.  
A) Mouse neutrophils were incubated with 0 (control) or 30 µg/ml of the indicated 
pentraxin, transferred to a fibronectin coated plate, and then activated with TNF-. After 
30 minutes, neutrophils bound to the plate were stained and counted, n=3. B,C) Mouse 
spleen cells were incubated with the indicated concentrations of pentraxin. After 5 days, 
the cells were fixed, stained, and fibrocytes were counted, n=3-6. D,E) Mouse bone 
marrow-derived macrophages were polarized for 3 days in serum-free medium 
containing 0 (control) or 10 µg/ml of the indicated pentraxin. Cells were then fixed and 
stained for CD206 and ICAM-I, n=3. F) Macrophages were polarized as in 1d and then 
soluble IL-10 levels in the supernatants were measured by ELISA, n=3-8. n.s (not 
significant relative to the control), *P <0.05 (t-test), (D) ×P<0.05 (t-test relative to SAP 
in C57BL/6). (a-f) Values are mean ± SEM. (B) Data were fit to sigmoidal dose 
response curves with a variable Hill coefficient or (C) a line. 
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reason for this functional difference is sequence divergence between SAP and CRP.  
However, we previously found that mutating SAP surface amino acid residues that are 
different between SAP and CRP has only a modest effect on SAP function (108). An 
alternative cause of this functional difference may be a difference in SAP and CRP 
glycosylation: SAP is glycosylated at N32 with α(26)-linked terminal sialic acids 
(119), whereas CRP has no glycosylation (119). To determine if the SAP glycosylation 
affects its function, we enzymatically removed the terminal sialic acids with 
neuraminidase. The resulting desialylated SAP (SAP (NA)) could no longer be detected 
on western blots stained with Sambucus Nigra lectin, which binds preferentially to 
α(26)-linked terminal sialic acids (Fig. 15, A and B).  
SAP and CRP reduce TNF- induced human neutrophil adhesion to fibronectin 
(20) (Fig. 15C). Compared to SAP, SAP (NA) had a reduced effect on human neutrophil 
adhesion and was unable to completely inhibit fibrocyte differentiation when added to 
human PBMCs and mouse spleen cells (Fig. 15, C, D and E). Conversely, we mutated 
CRP at position 32 from an alanine to an asparagine to engineer a glycosylated CRP. 
The mutated CRP (CRP A32N) was glycosylated and had a lower mobility on SDS-
PAGE gels compared to CRP (Fig. 15, A and B). Similar to CRP and SAP, CRP A32N 
reduced human neutrophil adhesion (Fig. 15C). As previously observed (54), CRP had 
no significant effect on human or murine fibrocyte differentiation (Fig. 15, E and F). 
However, CRP A32N inhibited fibrocyte differentiation when added to human PBMC or 
spleen cells from C57BL/6 mice or FcR quad KO mice (Fig. 15, E and F). 
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In addition to regulating fibrocyte differentiation, SAP and CRP can polarize 
macrophages (64, 70, 71). To examine the role of SAP glycosylation on macrophage 
polarization, we added pentraxins to mouse and human macrophages. SAP and CRP 
A32N increased the expression of the M2 marker CD206 on mouse bone marrow-
derived macrophages (Fig. 15G), while CRP and SAP (NA) increased the expression of 
the M1 marker ICAM-I (123) (Fig. 15G). We observed a similar trend in human 
monocyte-derived macrophages, where SAP and CRP A32N increased the expression of 
the M2 marker CD163 (63) while SAP (NA) and CRP increased the expression of the 
M1 marker ICAM-I (Fig. 15H). Together, these results indicate that SAP glycosylation 
is a key mediator of its effect on innate immune cells and can explain the functional 
differences between SAP and CRP. 
 
SAP but not CRP binds to DC-SIGN to regulate innate immune cells 
The α(26)-linked terminal sialic acids on sIgG can bind to DC-SIGN  to alter 
IgG responses (117). Since SAP shares the same type of glycosylation as sIgG (119), 
and SAP and the Fc domain of IgG bind to FcR , we examined the possibility that SAP 
might bind to DC-SIGN. We expressed DC-SIGN on HEK293 cells and measured SAP 
binding to the transfected cells (Fig. 16A and Fig. S5, A and B). We used mock-
transfected HEK293 cells to estimate the non-specific binding (Fig. S5). SAP bound to 
DC-SIGN with a KD of 2.3 ± 1 µg/ml (19 ± 8 nM) and a Hill coefficient of 0.7 ± 0.3. 
However, SAP (NA) and CRP did not show detectable binding (Fig. 16A). This suggests 
that SAP may bind to DC-SIGN through its terminal sialic acids to alter immune  
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Figure 15: SAP glycosylation regulates neutrophil adhesion, monocyte 
differentiation, and macrophage polarization.  
A) Desialylated SAP (SAP (NA)), SAP, glycosylated CRP (CRP A32N), and CRP were 
electrophoresed on a SDS-PAGE gel and stained with silver stain. B) A western blot of 
the samples shown in 2a was stained with biotinylated Sambucus Nigra lectin to detect 
α(2,6)-linked terminal sialic acids. C) Human neutrophils were incubated with 0 
(control) or 10 µg/ml of the indicated pentraxin, transferred to a fibronectin coated plate, 
and then activated with TNF-. The adherent neutrophils were then counted, n=3-5. D) 
Human PBMC were incubated with the indicated concentrations of pentraxins. After 5 
days, fibrocytes were counted, n=3-5. E) Mouse spleen cells were incubated in the 
presence or absence of 10 µg/ml of the indicated pentraxin. Fibrocyte counts were 
normalized to the no-pentraxin control, n=3. F) Human PBMC were incubated with the 
indicated concentrations of pentraxin. After 5 days fibrocytes were counted, n=3-5. G) 
Mouse C57BL/6 bone marrow-derived macrophages were polarized for 3 days in serum-
free medium containing 0 (control) or 10 µg/ml of the indicated pentraxins. Cells were 
then stained for the indicated markers, n=3. H) Human monocyte-derived macrophages 
were polarized by 3 µg/ml of the indicated protein. Macrophages were then stained for 
the indicated markers, n=3. *P<0.05, **P<0.01 (t-test). (E) + P<0.05 (t-test relative to 
the no-protein control). (C-H) Values are mean ± SEM. (D-E) Data were fit to sigmoidal 
dose-response curves with a variable Hill coefficient or a line where appropriate. 
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responses. To test this possibility, we examined the effect of SAP on spleen cells from 
mice lacking the mouse orthologue of human DC-SIGN, SIGN-R1. The absence of 
SIGN-R1 significantly decreased the inhibitory effect of SAP on fibrocyte 
differentiation (Fig. 16B). CRP A32N and PTX3 were also unable to alter fibrocyte 
differentiation from spleen cells of SIGN-R1 deficient mice, suggesting that SIGN-R1 
might mediate CRP A32N and PTX3 effects on fibrocyte differentiation (Fig.16C and 
Fig. S6). 
DC-SIGN is expressed on macrophages, dendritic cells, and monocytes (116, 
117). We also detected cell-surface DC-SIGN on human neutrophils and a subpopulation 
of human lymphocytes (Fig. S5C). As the majority of cells expressing DC-SIGN appear 
to respond to SAP, we examined how DC-SIGN activation by antibodies against the 
extracellular domain of this receptor can alter neutrophil, monocyte, and macrophage 
function. Some, but not all, anti-human DC-SIGN antibodies decreased human 
neutrophil adhesion to fibronectin (Fig. 16D), and inhibited human fibrocyte 
differentiation with an IC50 of 2.4 ± 0.4 µg/ml (Fig. 16E and Fig. S7, A and B). A 
different subset of anti-DC-SIGN antibodies also altered macrophage phenotype and 
increase CD163 expression similar to SAP and CRP A32N (Fig. 16F and Fig. S7C).  
Antibodies against DC-SIGN may also interact with the FcR through their Fc 
region, therefore confounding our observations and resulting in FcR dependent 
responses. To rule out this possibility, we used synthetic ligands of DC-SIGN that block 
the binding of HIV to this receptor (124). Some DC-SIGN ligands have previously been 
shown to activate DC-SIGN (125). When added to immune cells, a polycyclic  
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Figure 16: DC-SIGN activation affects neutrophils and monocyte-derived cells.  
A) HEK293 cells expressing DC-SIGN were incubated with fluorescently labeled SAP, 
CRP, or SAP (NA). The cells were then washed, and the binding of the labeled protein 
to the cells was measured by flow cytometry. Mock transfected cells were used to 
estimate the non-specific binding, n=3. B) The effect of SAP on fibrocyte differentiation 
in C57BL/6 and SIGN-R1 deficient mice was assessed, n=3-5. C) Mouse spleen cells 
were incubated in the presence or absence of 10 µg/ml of the indicated pentraxin. 
Fibrocytes were counted as a percent of the no-pentraxin control, n=3-5. D) Human 
neutrophils were incubated with increasing concentrations of anti-DC-SIGN antibodies 
and then neutrophil adhesion to fibronectin was assessed, n=3. E) Human PBMCs were 
incubated with the indicated concentrations of a rabbit anti-DC-SIGN antibody or a 
rabbit isotype control. After 5 days, fibrocytes were counted, n=3-5. F) Human 
monocyte-derived macrophages were polarized with 1 µg/ml of the indicated antibody. 
Macrophages were then fixed and stained for CD163, n=3. G) The effect of compound 1 
on human neutrophil adhesion to fibronectin was assessed, n=3. H) The effect of 
compound 1 on human fibrocyte differentiation, n=3. I) Macrophage polarization by 10 
pg/ml of compound 1 was examined in human monocyte-derived macrophages, n=3. 
*P<0.05 (t-test). (A-I) Values are mean ± SEM. (A) Curves are fits to models of one-site 
binding with variable Hill coefficient where appropriate. (B,D,G,H) Data were fit to 
sigmoidal dose response curves with a variable Hill coefficient. 
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aminothiazole DC-SIGN ligand (compound 1; shown as compound 4 in Fig. 2 of 
reference (124)) decreased human neutrophil adhesion (IC50 of 1.7 ± 0.3 µg/ml and a 
Hill coefficient of 2.6 ± 0.2) (Fig. 16G) and inhibited human fibrocyte differentiation 
(IC50 = 1.2 ±  0.4 pg/ml, Hill coefficient = 0.30 ± 0.01) (Fig. 16H) without affecting cell 
viability below 0.1 µg/ml (Fig S8, A and B). Compound 1 also promoted M2 
macrophages as measured by CD163 expression (Fig. 16I). Compound 1 similarly 
reduced neutrophil adhesion, inhibited fibrocyte differentiation, and promoted M2 
macrophages in FcγR quad KO cells (Fig. S9). However, compound 1 did not affect 
fibrocyte differentiation when added to SIGN-R1 deficient cells (Fig S8C). These data 
suggest that DC-SIGN activation by antibodies or a synthetic ligand is sufficient to 
mimic some SAP functions. This SAP-DC-SIGN interaction may also contribute to the 
differences in SAP and CRP effects on the innate immune system. 
 
Compound 1 reduces neutrophil accumulation in the lungs of bleomycin-treated mice 
SAP and PTX3 can regulate neutrophil recruitment in mice (20, 126). To 
determine if SIGN-R1 activation similarly affects neutrophils in mice, WT mice were 
given bleomycin to induce acute lung inflammation. We then injected the mice with 
compound 1 and examined neutrophil accumulation in the lungs. We did not use anti-
SIGN-R1 antibodies because they would activate both SIGN-R1 and FcR, therefore 
confounding the results. As previously observed (89), oropharyngeal instillation of 
bleomycin significantly increased the number of Ly6G
+
 neutrophils in the lungs (Fig. 
17). When mice were injected with compound 1 at 0.1 mg/kg on days 1 and 2 after 
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bleomycin, there was a significant decrease in Ly6G
+
 cells in the lungs at day 3 
compared to the bleomycin control (Fig. 17). Bleomycin treatment also resulted in a 
significant increase in CD11b
+
 macrophages and CD45
+
 immune cells in the 
bronchoalveolar lavage (BAL) fluid (Fig. 17B). This increase in infiltrating cells was 
absent when mice were given compound 1 (Fig. 17B). Additionally in the post-BAL 
lungs, compound 1 reversed a bleomycin-induced decrease in CD11c
+
 cells (Fig. 17C). 
However, compound 1 did not alter the number of CD11b
+
 macrophages in the lungs 
compared to the bleomycin control (Fig. 17C). Our results indicate that DC-SIGN 
ligands such as compound 1 can, similar to SAP and PTX3 (20, 126), regulate neutrophil 
accumulation in mouse lungs following an insult. 
 
Compound 1 alleviates pulmonary fibrosis in mice 
Compound 1 alters macrophage phenotype and inhibits fibrocyte differentiation 
in a manner similar to SAP. As macrophages and fibrocytes are implicated in fibrosing 
diseases (45, 127), we determined if DC-SIGN activation by compound 1 in a murine 
bleomycin model of pulmonary fibrosis was sufficient to mimic SAP and alleviate 
fibrosis. As previously observed (122), oropharyngeal instillation of bleomycin resulted 
in increased collagen deposition and recruitment of CD11b
+
 macrophages to the lungs 
(Fig. 18). Daily injections of compound 1 at doses as low as 0.001 mg/kg significantly 
decreased collagen deposition in the lungs and improved overall health as indicated by 
weight change (Fig. 18, A and B and Fig. S10A). In addition, compound 1 significantly 
reduced the number of CD11b
+
 macrophages compared to the bleomycin control (Fig.  
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Figure 17: Compound 1 decreases neutrophil accumulation in the lungs of mice 
following bleomycin treatment.  
A) C57BL/6 mice received oropharyngeal bleomycin on day 0 to induce acute 
respiratory distress syndrome. The control mice received saline. Mice were then treated 
with intraperitoneal injections of 0.1 mg/kg of compound 1 (C1) or an equal volume of 
vehicle control on days 1 and 2. On day 3 the mice were euthanized and lungs after BAL 
were stained for the neutrophil marker Ly6G. Images are representative of 3 independent 
experiments. Bar is 100 µm. B) BAL cells were stained for the indicated markers, n=4. 
C) After collecting the BAL, lungs were stained for the indicated markers, n=4. *P<0.05 
(1-way ANOVA, Holm-Bonferroni posttest). (B-C) Values are mean ± SEM. 
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18, C and D). These data suggest that compound 1, similar to SAP, can alleviate 
pulmonary fibrosis and inflammation in mice. 
 
Interleukin 10 deficient mice are insensitive to the anti-inflammatory effect of compound 
1 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that is released in 
response to DC-SIGN activation (118). IL-10 is also necessary for the anti-fibrotic effect 
of SAP in a mouse model of renal fibrosis (23, 64). As compound 1 activates DC-SIGN 
and mimics some SAP functions, we examined the efficacy of compound 1 on 
pulmonary fibrosis in IL-10 deficient mice. In IL-10 deficient mice, bleomycin 
instillation significantly increased collagen deposition and CD11b
+
 and CD11c+ 
macrophages in lungs (Fig. 19). Oropharyngeal instillation of bleomycin also resulted in 
significant decrease in body weight (Fig. S10B). Daily injections of 0.1 mg/kg of 
compound 1 had no significant effect on collagen deposition, CD11b
+
 macrophage 
accumulation, CD11c
+
 cell accumulation, or body weight in IL-10 deficient mice (Fig. 
19 and Fig. S10B). These results suggest that IL-10 is necessary for the anti-fibrotic 
effects of compound 1 in a mouse bleomycin model of pulmonary fibrosis. 
 
Lung conducting airway epithelial cells express SIGNR-R1 and IL-10  
Since compound 1 binds SIGN-R1 to regulate monocyte functions in mice, we 
examined the expression of this receptor in mouse lungs. We found that SIGN-R1 was 
expressed on Epcam-1
+
 lung epithelial cells and on CD45
+
 cells (Fig. 20A). To  
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Figure 18: Compound 1 alleviates pulmonary fibrosis in mice.  
A) C57BL/6 mice received oropharyngeal bleomycin (Bleo) on day 0 to induce 
pulmonary fibrosis. Control mice received saline. Mice were then injected with 
compound 1 (C1) or vehicle control at the indicated dose daily starting on day 1 and 
ending on day 20. On day 21, mice were euthanized and after collecting BAL fluid, 
lungs were stained with PicroSirius red to estimate collagen deposition. Images are 
representative of 3 different experiments. Bar is 200 µm. B) Quantification of 
PicroSirius red staining, n=3. C) BAL cell were stained for CD11b, n=3. Rat IgG1 was 
used as the isotype control. D) After collecting BAL, lungs were stained for CD11b, 
n=3. *P<0.05, **P<0.01, ***P<0.001(1-way ANOVA, Holm-Bonferroni posttest). (B-
D) Values are mean ± SEM. 
67 
determine the source of IL-10, we stained mouse lungs for Epcam-1, CD45, and IL-10 
by immunofluorescence. In saline treated mice, Epcam-1
+
 epithelial cells but not CD45
+
immune cells expressed detectable levels of IL-10 (Fig. 20, B and C). However when 
mice were treated with bleomycin, the number of IL-10-expressing epithelial cells 
(Epcam-1
+
) significantly decreased (Fig. 20D). This decrease in IL-10
+
 Epcam-1
+
 cells
was reversed when mice were injected with compound 1 or SAP (Fig. 20D). These 
results suggest that compound 1 and SAP can bind to SIGN-R1 on Epcam-1
+ 
epithelial
cells to induce IL-10 expression and reduce inflammation. 
Discussion 
SAP and CRP bind FcR and regulate the innate immune system and fibrosis (23, 
83, 108). In this report, we found that in the absence of all FcR, SAP still reduces 
neutrophil adhesion, inhibits fibrocyte differentiation, and alters macrophage phenotype. 
Conversely, CRP requires FcR to reduce neutrophil adhesion and promote IL-10 
secretion by macrophages, but not to increase ICAM-I
+
 macrophages. These results
indicate that FcR mediate only a few aspect of SAP function, but many effects of CRP. 
These observations suggest the presence of additional pentraxin receptors. We identified 
an additional SAP receptor as DC-SIGN, found that SAP binds to this receptor through 
its glycosylation, and observed that a DC-SIGN ligand mimics some SAP functions in 
vitro and in animal models of acute lung injury and pulmonary fibrosis. The DC-SIGN 
ligand alleviates pulmonary fibrosis in mice through an IL-10 dependent mechanism, 
with the IL-10 most likely originating from the epithelial cells in the lungs. The effect of 
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Figure 19: Interleukin-10 is necessary for the anti-fibrotic effect of compound 1.  
A) IL-10
 
deficient mice were given oropharyngeal bleomycin or saline (control) on day 
0. The bleomycin-treated mice were injected with 0.1 mg/kg compound 1 (C1) or an 
equal volume of vehicle control daily starting on day 1 and ending on day 20. On day 21, 
mice were euthanized and after collecting BAL fluid, lungs were stained with 
PicroSirius red to estimate collagen deposition, n=3. B) BAL cells were stained for the 
indicated markers, n=3. Rat IgG1 was used as the isotype control. C) After collecting 
BAL, lungs were stained for the indicated markers, n=3. *P<0.05 (1-way ANOVA, 
Holm-Bonferroni posttest). (A-C) Values are mean ± SEM. 
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Figure 20: Murine lung epithelial cells express SIGN-R1 and IL-10. 
 A) Mouse lungs following BAL were stained for the indicated markers. Images are 
representative of 3 different experiments. Bar is 50 µm. B) Mouse lungs were stained for 
Epcam-1 and IL-10. Images are representative of 3 different experiments. Bar is 50 µm. 
C) The expression of CD45 and IL-10 in mouse lungs post-BAL was assessed by 
immunofluorescence. Images are representative of 3 different experiments. Bar is 50 
µm. D) The number of Epcam-1
+
 cells expressing IL-10 in mouse lungs after BAL was 
quantified and compared between different treatment groups, n=3. *P<0.05, **P<0.01, 
(1-way ANOVA, Holm-Bonferroni posttest). (D) Values are mean ± SEM. 
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CRP on the expression of ICAM-I on macrophages appeared to be independent of FcR, 
and since CRP does not bind DC-SIGN, an unknown receptor thus mediates some CRP 
signaling. 
The FcR have been viewed as the main targets for SAP and CRP in the innate 
immune system (10, 83). Our data counter this view, as SAP is able to regulate the 
innate immune cells in absence of all FcR. In fact, SAP is a more potent polarizer of 
FcR deficient macrophages than WT macrophages, suggesting that some of the FcR 
may counteract the effect of SAP. In agreement with this, anti-DC-SIGN antibodies, 
which interact with both FcR and DC-SIGN, reduced but did not abolish neutrophil 
adhesion, whereas a DC-SIGN ligand completely abolished this adhesion. A similar 
trend was observed with SAP, which is a more potent inhibitor of FcR deficient 
neutrophil adhesion than WT neutrophils. However, this effect of FcR appears to be 
cell-type dependent as both the FcR and DC-SIGN seem to act cooperatively to inhibit 
monocyte to fibrocyte differentiation. Both DC-SIGN and FcR regulate the activity of 
Src kinases in innate immune cells (84, 128). The antagonism of DC-SIGN and FcR 
signaling in some cells, and the cooperativity of DC-SIGN and FcR signaling in other 
cells, may thus be due to their differential effects on Src kinases. 
Although DC-SIGN/ SIGN-R1 is considered to be primarily expressed by innate 
immune system cells, the majority of SIGN-R1 staining in mouse lungs was on Epcam-
1
+ 
epithelial cells. These SIGN-R1
+
 Epcam-1
+ 
expressed high levels of IL-10. Following 
a bleomycin insult, at day 21, although there was no appreciable reduction in the number 
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of Epcam-1+ cells, there was a significant decrease in the number of IL-10
+
 Epcam-1
+
 
cells. IL-10 inhibits apoptosis of epithelial cells (129) and increases the clearance of cell 
debris (130). As such, up-regulation of IL-10 by SAP or compound 1 may have a 
protective effect on lungs by limiting tissue damage and inflammatory responses. A 
similar role has been previously observed for epithelial cell-derived IL-10 in mouse 
models of inflammatory bowel disease (131). Alternatively, it is possible that IL-10 
expression in SIGN-R1
+
 epithelial cells is a function of their health. However, this is 
unlikely because our studies in IL-10 deficient mice suggest a critical role for IL-10 in 
the anti-fibrotic role of compound 1.  
Together, our data indicate that SAP binds DC-SIGN/SIGN-R1 to regulate innate 
immune cells and epithelial cells. Through its interaction with DC-SIGN, SAP 
distinguishes itself functionally from CRP. This suggests that DC-SIGN/SIGN-R1 is a 
key regulator of the innate immune system and is thus an interesting therapeutic target. 
Additionally, the functional interaction of SAP and PTX3 with DC-SIGN suggest that 
these pentraxins may regulate dendritic cells, and thus possibly the adaptive immune 
system. 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
Fibrosing diseases such scleroderma, pulmonary fibrosis, and renal fibrosis are 
caused by aberrant scar tissue formation in internal organs and are associated with 45% 
of deaths in the U.S. (73). The two short pentraxins Serum Amyloid P (SAP) and C-
reactive protein (CRP) regulate fibrosis by effecting neutrophils, monocytes, and 
macrophages (20, 23, 25, 64, 100). All SAP and CRP functions are thought to be 
mediated through Fc receptors which include the FcRI, FcRII, and FcRIII (23, 57, 
58). However, despite extensive similarities between SAP and CRP and their 
comparable affinities for the FcR, they generally have opposing effects on the innate 
immune system. What causes these functional differences is not known.  
In the work presented in this dissertation, I found through site-directed 
mutagenesis that SAP effects fibrocyte differentiation and neutrophil adhesion in part by 
binding FcRI on monocytes and FcRIIa on neutrophils. Further experimentation 
revealed that FcR are not necessary for SAP effects as in the absence of all FcR, SAP 
still reduced neutrophil adhesion, inhibited fibrocyte differentiation, and altered 
macrophage phenotype.  Conversely, CRP required FcR to reduce neutrophil adhesion 
and promote IL-10 secretion by macrophages, but not to alter macrophage phenotype. 
These results indicate that FcR play a more significant role in CRP responses than in 
SAP effects providing a potential explanation for the difference in SAP and CRP 
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function. These observations also indicate the presence of additional SAP and CRP 
receptors. I identified DC-SIGN as a novel SAP receptor, found that SAP bound to this 
receptor through its glycosylation, and observed that a DC-SIGN ligand mimics SAP 
functions in vitro and in animal models of acute lung injury and pulmonary fibrosis. The 
DC-SIGN ligand alleviated pulmonary fibrosis in mice through an IL-10 dependent 
mechanism, with the IL-10 most likely originating from the epithelial cells in the lungs. 
Together, the results in this dissertation indicate that SAP binds to DC-SIGN to regulate 
the innate immune system differently from CRP, and that DC-SIGN ligands and 
antibodies can be used as novel anti-fibrotic therapies. 
The data presented in this dissertation indicate that DC-SIGN is the main 
mediator of SAP effect while the FcR play a secondary role. These findings are in stark 
contrast to the current model of pentraxin function which suggests that SAP and CRP 
affect the innate immune system mainly through the FcR. However, despite the 
apparent contradiction the data presented here does not refute the previous studies on the 
role of FcR in SAP signaling. It simply challenges the interpretation of those studies. 
Previous studies have examined the role of FcR in SAP function by using Fc common 
-chain deficient mice that have defects in FcR signaling (23, 107). The results from 
these studies were used to suggest a role of FcR in SAP signaling. However, only two 
out of the four FcR use the common -chain (84). Furthermore, excluding the FcR 
there are additional ~10 receptors that use the common -chain for signaling (132). 
Therefore, in vivo studies on -chain deficient mice cannot be used to clearly indicate the 
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role of FcR in pentraxin response. These studies simply suggest a role for -chain 
dependent signaling in SAP function. 
Glycosylated proteins bind DC-SIGN in a Ca
2+ 
dependent manner to activate the 
receptor and initiate a signal transduction pathway that involves the Src family of 
kinases(118). The activation of Src kinase by DC-SIGN ultimately leads to up-regulation 
of anti-inflammatory proteins such as IL-10. The FcR also use the Src family of kinases 
to affect immune response (84). The convergence of DC-SIGN and FcR signaling at 
Src kinases suggest a hypothetical mechanism by which activation of FcR can alter DC-
SIGN signaling. In accordance with this hypothetical DC-SGIN-FcR cross talk, I 
observe that in FcR deficient macrophages, SAP was a more potent polarizer of 
macrophages suggesting that FcR signaling may antagonize DC-SIGN activation by 
SAP. A similar trend was observed with neutrophils where FcR deficient cells were 
modestly more sensitive to SAP. Conversely, SAP seems to require both the FcR and 
DC-SIGN to completely inhibit fibrocyte differentiation from monocytes. Therefore, 
although FcR may not be necessary for SAP responses, the activation of FcR by SAP 
may regulate signaling by DC-SIGN. 
In this dissertation, I observed that SIGN-R1
+
 Epcam-1
+   
epithelial cells express 
high levels of IL-10 under non-inflammatory conditions. However, following a 
bleomycin insult, there was a significant decrease in the number of IL-10
+
 Epcam-1
+
 
cells. IL-10 inhibits apoptosis of epithelial cells (129) and increases the clearance of cell 
debris (130). As such, up-regulation of IL-10 by SAP or compound 1 (DC-SIGN ligand) 
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may have a protective effect on lungs by limiting tissue damage and inflammatory 
responses. A similar role has been previously observed for epithelial cell-derived IL-10 
in mouse models of inflammatory bowel disease (131). In agreement with this, in IL-10 
deficient mice our DC-SIGN ligand has no anti-fibrotic effect. 
DC-SIGN/ SIGN-R1 is considered to be primarily expressed by innate immune 
cells(118). However, SIGN-R1 staining in mouse lungs revealed that Epcam-1
+ 
epithelial cells were the main source of this receptor. In humans, in addition to DC-
SIGN which is mainly found on immune cells there is L-SIGN. The C-type lectin L-
SIGN has a similar ligand recognition profile to DC-SIGN (118). But, L-SIGN is mainly 
found on liver endothelial cells and lung cells (118, 133). Hence, SIGN-R1 on mouse 
lung epithelial cells may be functionally equivalent to L-SIGN and not DC-SIGN in 
humans. 
DC-SIGN/SIGN-R1 is found on the surface of dendritic cells, monocytes, 
macrophages, neutrophils, lung epithelial cells, and a subpopulation of lymphocytes in 
the blood ( (118) and Fig S5). The observation that SAP binds to DC-SIGN suggest 
novel targets of this protein in the body. In particular, the presence of DC-SIGN on 
dendritic cells and .a sub-population of lymphocytes indicates a direct mechanism by 
which SAP may alter an adaptive immune response. Furthermore, the potential 
regulation of epithelial cells by SAP is significant as not much is understood about how 
the immune system regulates the epithelial cells under normal and diseased conditions 
(134).  
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This dissertation suggests that despite the current model, FcR receptors are 
dispensable for SAP function. SAP primarily uses DC-SIGN/SIGN-R1 to regulate innate 
immune cells and epithelial cells. Also, through its interaction with DC-SIGN, SAP 
distinguishes itself functionally from CRP explaining why two closely related proteins 
have opposite functions. Lastly, the data presented here suggest that DC-SIGN/SIGN-R1 
is a key regulator of the innate immune system and is thus an interesting therapeutic 
target.  
Future work 
There are number of ways the work in this dissertation can be developed. Some 
are as followed: 
1. In absence of the FcR, macrophages respond to CRP. However, CRP 
does not bind DC-SIGN. 
a. Hence, what is the unknown CRP receptor on macrophages?  
b. How does this receptor regulate CRP responses in other cell 
types?  
c. What happens to immune responses when this CRP receptors in 
deleted from mice? 
2.  SAP and PTX3 interact with DC-SIGN.  
a. How do DC-SIGN deficient mice respond to SAP and PTX3? 
b.  Does lacking DC-SIGN make the mice more susceptible to 
fibrosis or autoimmune disorders?  
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3. DC-SIGN activation has been shown to alleviate a multitude of immune 
related diseases such as inflammatory bowel disease. How would SAP 
affect these inflammatory disorders? 
4. SAP affects DC-SIGN epithelial cells in the lungs. A subpopulation of 
these DC-SIGN+ cells belong to type II alveolar cells that are 
differentiate and form other epithelial cells. These type II alveolar cells 
are implicated in lung regeneration and maintenance. How SAP affects 
the type II epithelial cells will provide valuable insight into how lungs are 
maintained and how they respond to infections and injuries.  
5.  FcR receptors seem to antagonize SAP signaling in mice.  
a. What are the underlying elements that contribute to this effect? 
b. How would mice respond to high levels of SAP in absence of all 
FcR receptors? 
6. SAP reduces neutrophil adhesion partly through its glycosylation which 
binds to DC-SIGN. 
a.  How does this interaction reduce adhesion?  
b. Is DC-SIGN an adhesion receptor that SAP blocks? 
c.  Does DC-SIGN activation lead to downstream events that alter 
neutrophil responses?  
d. How does SAP reduce neutrophil recruitment in mice?  
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7. IL-10 is necessary for the anti-fibrotic effect of compound 1. But does IL-
10 truly originate from epithelial cells? What would happen if IL-10 is 
knocked out in epithelial cells vs immune cells? 
8. SAP binds to FcR and DC-SIGN. How would deleting all FcR and DC-
SIGN affect SAP, CRP and PTX3 responses?  
9. There are 8 DC-SIGN receptors in mice. Do all bind SAP and contribute 
to its function? 
10. DC-SIGN and FcR signaling seem to converge on the Src kinases. How 
do the FcR and DC-SIGN “talk” to each other? 
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APPENDIX I 
NaCl POTENTIATES HUMAN FIBROCYTE DIFFERENTIATION
*
Summary 
Excessive NaCl intake is associated with a variety of fibrosing diseases such as 
renal and cardiac fibrosis. This association has been attributed to increased blood 
pressure as the result of high NaCl intake. However, studies in patients with high NaCl 
intake and fibrosis reveal a connection between NaCl intake and fibrosis that is 
independent of blood pressure. We find that increasing the extracellular concentration of 
NaCl to levels that may occur in human blood after high-salt intake can potentiate, in 
serum-free culture conditions, the differentiation of freshly-isolated human monocytes 
into fibroblast-like cells called fibrocytes. NaCl affects the monocytes directly during 
their adhesion. Potassium chloride and sodium nitrate also potentiate fibrocyte 
differentiation. The plasma protein Serum Amyloid P (SAP) inhibits fibrocyte 
differentiation. High levels of extracellular NaCl change the SAP Hill coefficient from 
1.7 to 0.8, and cause a four-fold increase in the concentration of SAP needed to inhibit 
fibrocyte differentiation by 95%.  Together, our data suggest that NaCl potentiates 
fibrocyte differentiation. NaCl-increased fibrocyte differentiation may thus contribute to 
NaCl-increased renal and cardiac fibrosis. 
*
 Reprinted under the Creative Commons Attribution License PLOS ONE. Cox, N., D. Pilling, and R. H. 
Gomer. NaCl potentiates human fibrocyte differentiation. PloS one. 2012;7(9):e45674. Copyright © 2012 
by the authors. 
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Introduction 
Fibrosing diseases such as pulmonary fibrosis, congestive heart disease, and 
renal fibrosis involve the formation of unwanted scar tissue in internal organs (73, 135). 
The scar tissue in fibrosis leads to organ malfunction and subsequent organ failure (73). 
Fibrosis is associated with approximately 45% of deaths in the U.S (73). Fibrosis 
involves infiltration of blood leukocytes into the affected organs, activation and/or 
appearance of fibroblast-like cells, tissue remodeling, and deposition of extracellular 
matrix proteins such as collagen (45, 81, 82, 136-138). Fibrosis can be caused by factors 
such as environmental toxins, or aberrant healing events (45). 
Fibrocytes are CD45
+
, collagen I
+
 fibroblast-like cells that have been implicated
in scar tissue formation and fibrosis (45, 82, 88, 136, 138). These cells share similarities 
with both blood leukocytes and tissue resident cells (81, 88). Fibrocytes, depending on 
the environmental cues, can express extracellular proteases, or matrix proteins such as 
collagen (45, 106). Fibrocytes differentiate from CD14
+
 monocytes (138). Following
their recruitment to a specific tissue, monocytes can differentiate into macrophages, 
dendritic cells, or fibrocytes (45, 65, 66). Serum Amyloid P (SAP), a pentameric protein 
from the pentraxin family of proteins, interacts with Fc receptors on monocytes to inhibit 
fibrocyte differentiation (13, 23, 54, 58). 
Monocytes leave the bone marrow and travel through the blood vessels until they 
are recruited into a specific tissue in response to chemokines. Afterward, they mature 
and differentiate under the influence of signaling molecules such as M-CSF, GM-CSF, 
IL-4, IL-13, and TGF-β1 (60, 139-141). One component of monocyte activation and 
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differentiation is a group of receptors belonging to the integrin family of proteins (142, 
143). Integrins are composed of α and β subunits (144). These proteins aid in monocyte 
adhesion to components of extracellular matrices and are central to inflammation, 
immunity, and homeostasis (145). The adhesive properties of integrins contribute to 
different patterns of monocyte differentiation under various conditions (142, 143, 146).  
Much remains to be understood about the mechanisms which trigger fibrosis and 
fibrocyte differentiation. Congestive heart disease and renal fibrosis have previously 
been linked to high NaCl intake in both humans and various animal models, but the 
exact mechanism underlying this connection is unknown (135, 147-151). Sodium and 
chloride ions contribute to the maintenance of electrical gradients across the membrane 
of many cells. In addition, sodium and chloride ions are used to absorb nutrients such as 
amino acids in the intestine, and regulate blood pressure and volume (147, 152, 153). 
The latter function of sodium and chloride ions has been the focus of many studies, since 
abnormalities in blood pressure have been associated with stroke, cardiac fibrosis, and 
renal fibrosis (148). 
It is generally accepted that there is a direct correlation between high salt intake 
and high blood pressure which in turn increases the chances of heart disease, stroke and 
renal failure (148). Until recently, it was believed that high blood pressure is the main 
contributor to heart disease and renal failure. However, animal and clinical studies have 
shown the deleterious effects (i. e. stroke, cardiac and renal fibrosis) of salt in the 
absence of increased blood pressure (147, 150, 154, 155). For instance, Wistar or 
Wistar-Kyoto rats exposed to salt overload develop cardiac, vascular, and renal fibrosis 
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without exhibiting a significant increase in blood pressure (149, 150). In addition, a 
connection between salt intake and fibrosis that is independent of high blood pressure 
has been previously established (147, 156, 157).  
A variety of studies indicate that different ions can modulate immune cell 
function. For instance, potassium channels and potassium transport affect the integrin-
dependent activation of the monocytic-derived cell line, THP-1 (158). Altering cation 
transport in murine erythroleukemia cells can induce differentiation (159). This, 
combined with the increased instances of fibrosing diseases in patients with high dietary 
salt intake, caused us to investigate the role of NaCl in the activation of monocytes and 
their subsequent differentiation into fibrocytes. Our results suggest that high 
concentrations of NaCl potentiate fibrocyte formation. 
 
Materials and Methods 
PBMC and monocyte isolation, cell culture, and fibrocyte differentiation assay 
Human blood was collected into heparin tubes (BD Bioscience, San Jose, CA) 
from adult volunteers who gave written consent and with specific approval from the 
Texas A&M University human subjects Institutional Review Board. Peripheral blood 
mononuclear cells (PBMCs) were isolated from the blood by Ficoll-Paque Plus (GE 
Healthcare Biosciences, Piscataway, NJ) and cultured in Fibrolife (LifeLine Cell 
Technology, Walkersville, MD) medium or where indicated in RPMI 1640 
(SigmaAldrich, St. Louis, MO) as described previously (86). CD14
+ 
monocytes were 
isolated by negative selection using magnetic Dynabeads (Dynal Biotech, Milwaukee, 
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WI ) as described previously (54). CD14
+ 
monocytes were plated in 96-well plates with 
5x10
4
 cells in 200 µl per well. After 5 days, the plates were air dried, fixed with 
methanol and stained using a Hema 3 staining Kit (Thermo Fisher Scientific, 
Milwaukee, WI) (86). Fibrocytes were identified and counted based on their elongated 
spindle-shaped morphology in five different 900 µm-diameter fields of view per well. 
 
Salt solutions and SAP purification 
One molar solutions of sodium chloride, sodium gluconate, sodium nitrate, and 
other salts were prepared in Fibrolife (LifeLine Cell Technology) basal medium or 
RPMI-1640 (SigmaAldrich) where indicated. The 1 M solutions were then filter 
sterilized using Acrodisc 0.2µm syringe filters (Pall, Port Washington, NY). Prepared 
solutions were then added to the wells at the indicated concentrations. Human Serum 
Amyloid P was purified from human serum as described previously (56). 
 
Immunohistochemistry 
PBMCs were cultured for 5 days on eight-well glass microscope slides (Thermo 
Fisher) as described previously (88). The cells were then air dried before fixation in 
acetone for 10 minutes. The cells were stained for CD13, CD45, CD68, Pro-collagen I 
(Developmental Studies Hybridoma Bank, University of Iowa), CD90, and Prolyl 4-
hydroxylase as described previously (88). 
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Adhesion Assay 
96-well polystyrene plates (BD Biosciences) were coated with 15 ug/mL of 
bovine plasma fibronectin (SigmaAldrich) or bovine collagen I (SigmaAldrich) for 1 
hour at 37˚C. The plate was then washed 3 times with PBS and then blocked with 4% 
BSA (SigmaAldrich, cat # A3059) in PBS for 1 hour at 37°C. Afterward, the plate was 
washed with serum-free medium, and peripheral blood mononuclear cells were 
incubated on the plate for 1 hour at 37˚C. The plates were then washed 3 times with PBS 
and adherent cells were counted in five 900 µm-diameter fields of view per well. 
PBMC/monocyte pulse experiment 
PBMCs or monocytes were incubated with additional concentrations of NaCl for 
the indicated times at 37˚C to determine the effect of additional of NaCl on fibrocyte 
differentiation during adhesion. Then, approximately 95% of the medium was gently 
removed, so as not to disturb the cells, and replaced with fresh medium. The cells were 
left to differentiate for 5 days. To determine the effect of NaCl on adherent cells, 
PBMCs or monocytes were incubated in 96-well plates for 1 hour at 37˚C, and the 
medium was then replaced with medium containing additional NaCl. The cells were left 
for 1 hour at 37˚C, and subsequently the medium was replaced with fresh medium with 
no additional NaCl. These cells were then left to differentiate for 5 days. To elucidate the 
effect of NaCl on PBMCs or monocytes before their adhesion to the plate, cells were 
placed in BSA-coated Eppendorf tubes for 1 hour in medium with additional NaCl at 
4˚C. The cells were then collected by centrifugation for 5 minutes at 300 x g. The 
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pelleted cells were resuspended in fresh medium and incubated in a 96-well plate for 5 
days at 37˚C to differentiate. 
Adhesion molecules and flow cytometry 
96-well polystyrene plates (BD Biosciences) were coated with 20 µg/mL of 
plasma fibronectin (SigmaAldrich) overnight at 4°C. The following day the coated wells 
were washed 3 x with PBS and blocked with 2% BSA in PBS. After blocking, the wells 
were washed 3 x with PBS and then the PBMCs were plated with 2x10
5 
cells per well in
the presence or absence of 25 mM additional NaCl for 1 hour at 37°C. After the 
incubation, the medium was replaced with PBS/ 10 mM EDTA and the plate was left at 
4°C for 15 minutes to detach the cells from the wells. The detached cells were then 
pelleted by centrifugation at 300 x g for 5 minutes and resuspended in 2% BSA in PBS. 
Following centrifugation, the cells were stained for CD11a (BioLegend, San Diego, 
CA), CD11b (BioLegend), CD11c (BioLegend), CD11b activation epitope (BioLegend), 
CD18 (BioLegend), CD18 activation epitope (Abd Serotec), CD31 (BioLegend), CD45 
(BioLegend), CD49d (BioLegend) and, CD62L (BioLegend) as described previously 
(88). 
Statistical analysis 
Data was analyzed by ANOVA (with Dunnett’s post test) or t-test when 
appropriate using Prism software (GraphPad software, San Diego, CA). Normality was 
tested using Shapiro-Wilk and D’Agostino-Pearson omnibus tests. 
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Results 
Additional NaCl can potentiate fibrocyte formation without influencing cell viability 
Since fibrocytes are implicated in fibrosing diseases, and NaCl may promote 
fibrosis, we examined the hypothesis that NaCl might affect fibrocyte differentiation. 
Using PBMCs from a variety of donors, we observed 600 to 2800 fibrocytes per 10
5
PBMCs in both Fibrolife and RPMI 1640 medium. For all donors, additional NaCl 
significantly potentiated fibrocyte differentiation, when compared to the control with no 
added NaCl (Fig. 21A and B). In Fibrolife medium, NaCl caused a maximum 
potentiation of fibrocyte differentiation at 30 mM additional NaCl. The [Na
+
] and [Cl
-
]
concentrations in Fibrolife medium are 126 mM and 119 mM, respectively. At 30 mM 
additional NaCl, both the sodium and the chloride concentration of Fibrolife medium 
([Na
+
] =156 mM, [Cl
-
]=144 mM) are in excess when compared to human blood
([Na
+
]=137 mM, [Cl
-
]=102 mM) (160, 161).  The [Na
+
] and [Cl
-
] concentrations in
RPMI 1640 medium are 134 mM and 107 mM, respectively. In RPMI 1640 medium, 
NaCl caused a maximum potentiation of fibrocyte differentiation at 20 mM additional 
NaCl, making [Na
+
] =154 mM, and [Cl
-
]=127 mM, again in excess when compared to
human blood. 
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Figure 21: Addition of NaCl to Fibrolife or RPMI based-medium increases 
fibrocyte differentiation.  
Human PBMCs were cultured for 5 days in serum-free medium in the presence of the 
indicated concentrations of additional NaCl in either Fibrolife (A) or RPMI (B) medium. 
Results are expressed as mean ± SEM, n=8. * indicates statistical significance with p < 
0.05, ** indicates P < 0.01, and *** indicates p < 0.001 by ANOVA compared to the no 
additional NaCl control. 
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To verify that the NaCl-induced spindle-shaped cells are fibrocytes, we stained PBMCs 
after 5 days of incubation with or without 25 mM additional NaCl in Fibrolife for 
fibrocyte markers. In the presence or absence of added NaCl, the elongated cells were 
positive for the fibrocyte markers CD13, CD45, CD68, 
 
pro-collagen I, and prolyl 4-
hydroxylase, and showed no observable staining for the fibroblast marker CD90, 
indicating that the elongated cells are fibrocytes, and that NaCl thus is increasing the 
number of fibrocytes
 
(Fig. 22). 
An increase in the total number of adherent cells in our assay plates could 
account for the increased fibrocyte count. To address this possibility, we counted the 
number of adherent cells after 5 days of incubation with additional NaCl.  At 30 mM 
additional NaCl and below, we observed no significant change in the number of adherent 
cells as the result of additional NaCl (Fig. 23). The addition of 60 mM additional NaCl 
did however decrease the number of adherent cells, indicating reduced cell viability. 
25 mM additional NaCl does not influence PBMC adhesion 
Fibrocytes differentiate from CD14
+
 monocytes (45, 138). Monocytes are
activated in response to adhesion to extracellular matrix proteins as well as tissue culture 
plates (65, 66). To understand the mechanism behind the potentiation of fibrocyte 
formation by NaCl, we investigated the influence of NaCl on the initial adhesion of 
PBMCs to plates, since such changes could influence PBMC activation and therefore 
differentiation. PBMC adhesion to collagen I-coated, fibronectin-coated, or un-coated 
tissue culture plates was not influenced by increasing NaCl concentrations (Fig. 24). 
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Figure 22: The elongated cells are fibrocytes.  
PBMCs were cultured in Fibrolife medium for five days in the presence or absence of 25 
mM additional NaCl. Cells were fixed and stained for the indicated markers. (A) The 
elongated spindle-shaped cells in the wells stained positive for CD13, CD45, CD68, 
Prolyl 4-hydroxylase (P-4-H), Pro-Collagen I (Pro-Col I) and had no apparent staining 
for the fibroblast marker CD90. Results are expressed as mean ± SEM, n=3. (B) Cells 
were stained with the indicated antibodies. Positive staining was identified by red for 
alkaline phosphatase staining and brown for peroxidase staining. Cells were 
counterstained blue with hematoxylin to identify nuclei. Size bar is 50 µm. 
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Figure 23: The effect of NaCl on adherent cells after 5 days.  
PBMCs were incubated with the indicated concentrations of added NaCl, and the 
number of adherent cells was counted after 5 days. Counts were then normalized to the 
control with no added NaCl (0).  Values are mean ± SEM, n=3.  *** indicates statistical 
significance by ANOVA compared to the control (p < 0.001). 
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Figure 24: NaCl does not influence the adhesion of PBMCs to plastic, plasma 
fibronectin or collagen I.   
PBMCs were incubated on uncoated polystyrene  plates, fibronectin coated plates, or 
bovine collagen I coated plates for one hour in the indicated concentrations of additional 
NaCl. The non-adhered cells were then rinsed off and the number of adherent cells were 
counted. Values are mean ± SEM, n=4. 
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However, as previously observed, more PBMCs adhered to fibronectin-coated plates 
than un-coated plates ((162) and Fig. 24). These results suggest that the observed 
increase in fibrocyte differentiation is not caused by changes in the ability of PBMCs to 
initially adhere to extracellular matrix proteins or tissue culture plates. 
Monocyte to fibrocyte differentiation is potentiated by additional NaCl 
The NaCl-induced increase in fibrocyte formation from PBMCs could be due to 
either secretion of a fibrocyte stimulating factor by non-monocytic cells, or via direct 
effect of NaCl on monocytes. To distinguish between these two possibilities, we isolated 
CD14
+ 
cells and examined their differentiation into fibrocytes in the presence of
increasing NaCl concentrations. We observed 1400 to 9200 fibrocytes per 10
5 
monocytes
from 3 different donors. When fibrocyte counts were compared to the no NaCl added 
control, fibrocyte differentiation was significantly increased by 20 mM to 30 mM 
additional NaCl (Fig. 25). This suggests that monocytes are directly influenced by the 
additional NaCl, and not through a secreted factor from CD14-negative cells. 
PBMCs and monocytes are influenced during their adhesion by additional NaCl 
PBMCs are activated by their adhesion to extracellular matrix proteins and tissue 
culture plates (163). To elucidate the mechanism behind the NaCl-induced increase in 
fibrocyte formation, we incubated PBMCs with additional NaCl before, during, and after 
their adhesion (Fig. 26). We observed that incubation of PBMCs with additional NaCl 
for one hour during their adhesion potentiated fibrocyte formation (Fig. 26). Incubation 
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Figure 25: NaCl directly potentiates the differentiation of monocytes into 
fibrocytes.  
CD14
+
 monocytes were incubated with the indicated additional concentrations of NaCl.
After 5 days, fibrocytes were counted. Values are mean ± SEM, n=3. * indicates p < 
0.05 compared to control (ANOVA). The absence of error bars indicate that error was 
smaller than the plot symbol. 
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Figure 26: The presence of additional NaCl during PBMC adhesion increases 
fibrocyte differentiation.  
PBMCs were incubated with additional NaCl , before, during, before, and after their 
adhesion to tissue culture treated plates. Values are mean ± SEM, n=6. *** indicates p < 
0.001 compared to control (t-test). The absence of an error bar indicates that the error 
was smaller than the line thickness. 
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of PBMCs with additional NaCl before or after their adhesion, or for 30 minutes during 
their adhesion, had no significant effect on fibrocyte formation (Fig. 26). These data 
suggest that NaCl influences fibrocyte precursors during adhesion. CD14
+ 
monocytes
were also incubated with additional NaCl before, during, and after adhesion. Similar to 
the results with PBMCs, incubation of monocytes with additional NaCl during their 
adhesion resulted in increased fibrocyte formation (Fig. 27). A 30-minute incubation of 
monocytes with 25 mM additional NaCl was sufficient for this potentiation. 
Since additional NaCl potentiates fibrocyte differentiation by influencing 
monocytes during their initial adhesion to the plate, we examined the effects of 25 mM 
additional NaCl on different adhesion molecules. We incubated PBMCs in the presence 
or absence of 25 mM additional NaCl for 1 hour at 37°C. Following incubation, the cells 
were stained for CD11a, CD11b, CD11c, CD11b activation epitope, CD18, CD18 
activation epitope, CD31, CD49d, and CD62L. The stained cells were subjected to flow 
cytometry and the CD14
+ 
monocytes were investigated for any change in the mentioned
adhesion molecules. We observed no change in the studied adhesion molecules as the 
result of additional NaCl (Fig. 28). 
Sodium nitrate but not sodium gluconate potentiates fibrocyte differentiation 
 Sodium nitrate and sodium gluconate are two classical sodium chloride 
substitutes used to probe chloride transport (164). Nitrate can bind and cross chloride 
channels (164-167). Gluconate only mimics the electrical charge of chloride while being 
unable to cross the majority of chloride channels (164-168). Sodium nitrate but not 
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Figure 27: The presence of additional NaCl during CD14
+ 
monocyte adhesion 
increases fibrocyte formation.  
Isolated monocytes were incubated with additional NaCl before, during, and after their 
adhesion to tissue culture treated plates. Values are mean ± SEM, n=4, ** indicates p < 
0.01, and *** indicates p < 0.001 compared to control (ANOVA). 
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Figure 28: Incubation of PBMCs with additional NaCl does not influence the cell-
surface levels of several adhesion molecules.  
PBMCs were incubated in the presence or absence of 25 mM additional NaCl for 1 hour 
at 37 °C and then stained for the indicated adhesion molecules. Monocytes were 
identified by their forward and side scatter characteristics and the expression of CD14. 
Flow cytometry plots are representative results from three separate donors. Histograms 
represent fluorescence intensity of the indicated marker in control cells (Black line) and 
NaCl treated Cells (Red line). 
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Figure 29: Sodium nitrate and potassium chloride potentiate fibrocyte 
differentiation.  
PBMCs were cultured with the indicated concentrations of additional (A) sodium 
chloride, sodium nitrate, or sodium gluconate, or (B) potassium chloride. Values are 
mean ± SEM, n=6. * indicates p < 0.05, and ** indicated p < 0.01 compared to control 
by ANOVA. 
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sodium gluconate potentiated fibrocyte differentiation (Fig. 29A). The response of 
PBMCs to sodium nitrate was similar to that of NaCl. This suggests that chloride 
transport across the membrane is a requirement for potentiation of fibrocyte 
differentiation by additional NaCl.  In addition to sodium nitrate and sodium gluconate, 
we investigated other compounds such as potassium chloride, rubidium chloride, cesium 
chloride, choline chloride, tetraethyl ammonium chloride, and monosodium glutamate. 
Adding 25 mM potassium chloride potentiated fibrocyte differentiation (Fig. 29B). 
Monosodium glutamate had no effect of fibrocyte differentiation but was toxic when 
added in excess of 50 mM. Choline chloride and rubidium chloride were toxic at 
concentrations higher than 4 mM, while cesium chloride and tetraethyl ammonium 
chloride were toxic at 2 mM (data not shown). 
NaCl interferes with the ability of Serum Amyloid P to inhibit fibrocyte differentiation 
Human Serum Amyloid P (hSAP) is a pentameric protein secreted from the liver 
that inhibits fibrocyte differentiation (54, 56, 77). The addition of 25 mM NaCl to the 
medium changed the Hill coefficient for the inhibition of fibrocyte differentiation by 
hSAP from 1.7 ± 0.1 to 0.7 ± 0.1 (mean ± SEM, n=5, p < 0.05 by t-test) (Fig. 30). In 
addition, adding 25 mM to the medium significantly inhibited the ability of high 
concentrations of hSAP to inhibit fibrocyte differentiation (Fig. 30). The data indicate 
that NaCl, in addition to potentiating fibrocyte differentiation, influences how hSAP 
inhibits fibrocyte differentiation. 
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Figure 30: NaCl interferes with the ability of hSAP to inhibit fibrocyte 
differentiation.  
PBMCs were incubated with or without additional 25 mM NaCl with the indicated 
concentrations of human SAP (hSAP). After 5 days, fibrocytes were counted. Values are 
mean ± SEM, n=5. * indicates p < 0.05 compared to SAP alone control (dashed line) by 
ANOVA. The absence of error bars indicate that error was smaller than the plot symbol. 
Lines are sigmoidal dose-response curves with variable Hill coefficient fit to the data. 
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Discussion 
Monocyte-derived fibrocytes are found in fibrotic lesions, skin wounds, and 
tumors (45, 47, 81, 82, 136, 169-171). We have shown here that the differentiation of 
human monocytes into fibrocytes in serum-free culture is potentiated by NaCl. This 
increase appears to be a direct effect of NaCl on monocytes. In patients with long-term 
elevated salt intake, there is a 5% increase in serum NaCl, raising [Na
+
] from 137 mM to
144 mM (161). In addition, food intake increases the blood sodium chloride level for ~4 
hours (172). We observed that 155 mM [Na
+
] and 130 [Cl-] potentiates fibrocyte
differentiation, and we hypothesize that this [Na
+
] and [Cl-] concentration could occur in
the serum or tissues of some individuals, at least for a few hours after eating a high-salt 
meal. However short, this transient increase could be sufficient to increase fibrocyte 
differentiation. 
In animal models and humans, increasing the extracellular osmolarity suppresses 
neutrophil functions such as cellular cytotoxicity and migration (173, 174). In addition, 
when tested on PBMCs in vitro, high salt increases the secretion of the pro-inflammatory 
cytokines IL-8 and TNF-α (175-177). These studies indicate that extracellular osmolarity 
can affect cells of the immune system. The increase in fibrocyte differentiation in 
response to increased NaCl could thus be due to increased osmolarity. However, we 
observed that adding up to 50 mM sodium gluconate or monosodium glutamate to the 
medium, which would also increase osmolarity, did not affect fibrocyte differentiation. 
Alternatively, an increase in cell proliferation as the result of additional NaCl could 
explain the increase in fibrocyte count. However, previous studies on the proliferation of 
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fibrocytes and fibrocyte precursors revealed no appreciable proliferation (51).  Thus, the 
observed increase in fibrocyte differentiation is probably not related to the medium 
osmolarity or cell proliferation in our in vitro assay and most likely involves a direct 
effect of NaCl on monocytes.  
When monocytes are activated following their recruitment into the tissue and 
adhesion to extracellular matrices, they undergo changes in gene expression and receptor 
levels (163, 178, 179). Following adhesion, monocytes are activated through a series of 
intracellular signaling events. We found that NaCl was most effective at increasing 
fibrocyte differentiation during monocyte adhesion. This was not accompanied by any 
changes in the expression of adhesion molecules CD11a, CD11b, CD11c, CD18, CD31, 
CD49d, and CD62L. In agreement with this, the additional NaCl did not influence the 
adhesive properties of monocytes to plasma fibronectin, collagen I, or un-coated tissue 
culture plates. Membrane potential and ion transport affect the activation of the 
monocyte-derived cell line THP-1 (158). It is thus possible that the effect of NaCl on 
fibrocyte differentiation is largely due to the increased NaCl affecting membrane 
potential and ion transport during the adhesion stage of monocyte activation. 
Ion channels, especially chloride channels, appear to affect cellular activation 
and differentiation. In osteoblasts, the chloride channel ClC-3 regulates osteo-
differentiation (180). The development and differentiation of keratinocytes is regulated 
in part by calcium-gated chloride channels (181). We observed that sodium nitrate but 
not sodium gluconate potentiated fibrocyte differentiation. Nitrate can pass through 
chloride channels, while gluconate cannot (164, 167).  Combined with the observation 
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that KCl potentates fibrocyte differentiation, this suggests that chloride ions might play a 
role in the NaCl-induced potentiation of fibrocyte differentiation. 
Monocyte activation and the subsequent differentiation into fibrocyte is 
influenced by variety factors such as SAP, M-CSF, GM-CSF, IL-4, IL-13 and, TGF-β1 
(51, 54, 138). These regulators of the immune system each use distinct and sometimes 
overlapping signaling transduction pathways making it difficult to identify the exact 
pathway responsible for the NaCl-induced increase in fibrocyte formation. 
Excessive intake of NaCl has been associated with high blood pressure, stroke, 
heart disease, and kidney disease (147, 148, 182, 183). The correlation between high salt 
intake and these diseases has generally been attributed to high blood pressure (148). 
However, studies in rats have questioned this correlation (149, 150).  In addition, two 
independent studies on cohorts of patients with high salt intake and fibrosis showed a 
connection between these two factors that was independent of high blood pressure (156, 
157). Here we have shown that fibrocyte differentiation can be potentiated by increasing 
extracellular NaCl levels in vitro. An intriguing possibility is that the link between high 
sodium chloride intake and fibrosis involves NaCl potentiating fibrocyte differentiation. 
In addition to participating in fibrosis, fibrocytes participate in wound healing 
(45, 55, 81). Our observations suggest that having ~155 mM [Na
+
] and ~ 130 mM [Cl
-
]
in wound dressings could not only potentiate fibrocyte differentiation but also influence 
the ability of hSAP to inhibit fibrocyte differentiation, and thus potentiate wound 
healing. 
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APPENDIX II 
SUPPLEMENTAL FIGURES 
Figure S 1: Identification of neutrophils, monocytes, and lymphocytes.  
Peripheral blood cells were isolated by density centrifugation and then stained for CD3, 
CD14, CD15, CD16, CD19, and CD45. Mouse IgG1 was used as the isotype control. 
Plots are representative of 3 independent experiments. Following staining, the cells were 
subjected to flow cytometry. (A) Neutrophils were positive for CD15, CD16, and CD45, 
(B) monocytes were positive for CD14, CD45, and some for CD16. (C) ~65-78% of 
lymphocytes were positive for CD3, ~5-10% for CD16, ~3-8% for CD19, and all for 
CD45. The cell distribution match previously published data. 
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Figure S 2: Alexa Fluor 647-labeled SAP (SAP-f) has no detectable functional 
defects.  
WT SAP was labeled with Alexa Fluor 647 and then tested for its effects on (A) 
neutrophil adhesion, (B) phagocytosis of Zymosan A, and (C) inhibition of fibrocyte 
differentiation. In (C) the data are fit to sigmoidal dose response curves with a variable 
Hill coefficient. Values are mean ± SEM, n=3. * represents p<0.05 and *** represents 
p<0.001 by t-test; n.s. indicates not significant. The absence of error bars indicates that 
the error was smaller than the line or plot symbol. 
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Figure S 3: The expression of Fc receptors on K562 cells and HEK293 cells.  
K562 cells, HEK293 or HEK293 cells expressing FcRI or FcRIIIb were gated on 
based on their forward scatter and side scatter characteristics and then stained for FcRI, 
FcRII, or FcRIII. Staining was measured by flow cytometry. Mouse IgG1 (black line) 
was used as the isotype control for all the antibodies used (red line). Plots are 
representative of 3 independent experiments.  
 132 
 
 
 
 
 
 
 
 
Figure S 4: Fc receptors are not necessary for some PTX3 effects on neutrophils 
and macrophages.  
A) Mouse neutrophils were incubated with 0 (control) or 1 µg/ml of PTX3, transferred 
to a fibronectin-coated plate, and then activated with TNF-. After 30 minutes, 
neutrophils bound to the plate were stained and counted, n=3. B,C) Mouse bone 
marrow-derived macrophages from C57BL/6 or FcR deficient mice were polarized for 
3 days in serum-free medium containing 0 (control) or 1 µg/ml of PTX3. Cells were then 
fixed and stained for CD206 and ICAM-1, n=3. D) C57BL/6 or FcR deficient 
macrophages were polarized and then soluble IL-10 levels in supernatants were 
measured by ELISA, n=3. *P<0.05,**P<0.01 (t-test). (A-D) Values are ± SEM. 
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Figure S 5: SAP binding to DC-SIGN
+
 HEK293 cells.  
A) The expression of DC-SIGN (red line) on a) HEK293 cells and HEK293 cells 
expressing DC-SIGN was determined by flow cytometry. Mouse IgG1 (blue line) was 
used as the isotype control. Plots are representative of 3 independent experiments. B) 
HEK293 cells expressing DC-SIGN were incubated with fluorescently-labeled SAP. The 
cells were then washed and the binding of the labeled SAP to the cells was measured by 
flow cytometry. Mock transfected cells were used to estimate the non-specific binding, 
n=3. C) The expression of DC-SIGN (red) on human leukocytes was determined by flow 
cytometry. Plots are representative of 3 individual experiments. (B) Values are mean ± 
SEM. (B) Curves are fits to models of one-site binding with variable Hill coefficient. 
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Figure S 6: SIGN-R1 is necessary for the effect of PTX3 on fibrocyte 
differentiation.  
Spleen cells from SIGN-R1 null
 
mice were incubated with the indicated concentrations 
of PTX3. After 5 days, cells were fixed, stained, and fibrocytes were counted, n=3. 
*P<0.05 (t-test). Values are mean ± SEM.
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Figure S 7: The effect of anti-human DC-SIGN antibodies on fibrocyte 
differentiation and macrophage polarization.  
A-B) Human PBMCs were incubated with the indicated concentrations of anti-DC-
SIGN antibodies or isotype controls. After 5 days, fibrocytes were counted, n=3. C) 
Human monocyte-derived macrophages were polarized for 3 days in serum-free medium 
with 1 µg/ml of the indicated antibody. Macrophages were then fixed and stained for 
CD163, n=3. *P<0.05 (t-test, relative to isotype control). (A-C) Values are mean ± 
SEM. 
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Figure S 8: Compound 1 inhibits fibrocyte differentiation through SIGN-R1 
without causing extensive cell death.  
A) Human PBMCs or B) C57Bl/6 mouse spleen cells were incubated with the indicated 
concentrations of compound 1. After 5 days, Alamar blue was used to estimate cell 
viability, n=3. C) Mouse spleen cells were incubated with increasing concentrations of 
compound 1. After 5 days, cells were fixed, stained, and fibrocytes were counted, n=4. 
Compound 1 inhibited murine fibrocyte differentiation with an IC50 of 91±47 pg/ml. 
*P<0.05, **P<0.01 (t-test). (A-C) Values are mean ± SEM. (C) C57BL/6 data were fit 
to a sigmoidal dose response curve with a variable Hill coefficient. 
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Figure S 9: Compound 1 inhibits neutrophil adhesion and fibrocyte differentiation 
and promotes M2 macrophages in absence of FcR. 
A) Mouse neutrophils were incubated with 0 (control) or 1 µg/ml of compound 1,
transferred to a fibronectin coated plate, and then activated with TNF-. After 30 
minutes, neutrophils bound to the plate were stained and counted, n=3. B) Mouse spleen 
cells were incubated with 0 or 1 ng/ml of compound 1. After 5 days, cells were fixed, 
stained, and fibrocytes were counted. C) Murine bone marrow-derived macrophages 
were polarized for 3 days in serum-free medium containing 0 or 10 pg/ml of compound 
1. Cells were then stained for CD206, n=3.*P<0.05, **P<0.01 (t-test). (A-C)Values are
mean ± SEM. 
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Figure S 10: The effect of compound 1 on mouse weights. 
 A) Mice in Figure 5 were weighed daily, n=3. B) IL-10 deficient mice were weighted 
daily, n=3. (A-B) Values are mean ± SEM. 
 
 
 
